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Abstract 
Human chromosome 15q11-q13.1 is associated with three distinct neurodevelopmental 
disorders—Angelman (AS), Prader-Willi (PWS), and 15q duplication (Dup 15q) 
syndromes. While symptomatic treatments are prescribed, no cure is currently available. 
Using iPSC technology, we established in vitro model systems from AS, PWS, and Dup 
15q patient samples to study chromosome 15q11-q13.1 gene regulation. We 
demonstrated that iPSCs maintain correct imprinting status at the PWS imprinting 
center after reprogramming and that UBE3A imprinting occurs in iPSC-derived neurons. 
Using CRISPR/Cas9 genome editing technology, we tagged UBE3A protein with GFP to 
create a reporter cell line. We also created RBFOX1 and RBFOX2 single and double 
knockouts and found that these alternative splicing factors are not required for neuron-
specific processing or expression of SNURF/SNRPN lncRNA. Using these disease-
specific iPSC models and the powerful CRISPR/Cas9 genome editing tool, we hope to 
elucidate underlying disease mechanisms and contribute to developing effective 
treatments for AS, PWS, and Dup 15q syndrome. 
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Chapter 1 
Chromosome 15q11-q13.1 and Genomic Imprinting Disorders 
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1.1 General Introduction 
Human chromosome 15q11-q13.1 is associated with three distinct 
neurodevelopmental disorders—Angelman (AS), Prader-Willi (PWS), and 15q 
duplication (Dup 15q) syndromes. Human chromosome 15q11-q13.1 harbors several 
common breakpoints composed of low-copy repeats or repetitive sequences that 
bracket imprinted as well as non-imprinted genes (Figure 1) (Amos-Landgraf et al., 
1999; Wang et al., 2004). When aligned inappropriately during meiosis, these 
breakpoints could lead to large de novo deletions or duplications, which are transmitted 
through the germ line. Paternal deletions cause PWS, maternal deletions result in AS, 
and duplications, often of maternal origin or epigenotype, lead to Dup 15q syndrome 
(Christian et al., 2008; Cook et al., 1997). Other than large deletions, AS and PWS can 
be caused by other genetic anomalies at chromosome 15q11-q13.1, which are 
discussed below. Overall, the incidence of each of these three disorders is 
approximately 1/15,000~1/30,000 live births (Battaglia, 2005; Cassidy and Driscoll, 
2009; Chamberlain and Lalande, 2010b). While symptomatic treatments are prescribed 
for AS, PWS, and Dup 15q patients, no cure is currently available. Similar to many other 
developmental disorders, early intervention is highly desirable for improved quality of life 
for these patients. 
1.2 Angelman, Prader-Willi, and 15q Duplication Syndromes 
AS patients have disproportionally small heads, known as microcephaly, and 
suffer from developmental delay, severe mental retardation, and frequent and intense 
seizures. Owing to absence of speech, motor dysfunction, and frequent smiling, AS 
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patients have been characterized as having a “happy puppet” affect (Lossie et al., 2001). 
AS is caused by the loss of maternal UBE3A, a gene residing in the imprinted domain of 
chromosome 15q11-q13.1 (Kishino et al., 1997). This results in the neuronal loss of an 
encoded ubiquitin protein ligase E3A (also known as E6-AP). In neurons, ubiquitin 
protein ligase E3A plays an important role in the regulation of synaptic proteolysis and 
has been implicated in synaptic plasticity as well as postsynaptic function (Greer et al., 
2010; Jiang et al., 1998; Weeber et al., 2003). In addition to maternal deletions (70%), 
maternally-transmitted loss-of-function mutations (10%), maternal imprinting defects 
(5%), and paternal uniparental disomy (5%) all lead to a loss of the ubiquitin protein 
ligase in brain and result in AS (Lalande and Calciano, 2007; Lossie et al., 2001). 
PWS patients suffer from mild to moderate cognitive deficits and display infantile 
hypotonia and failure to thrive. Soon after the first year of life, PWS patients develop 
obesity, followed by insatiable appetite, known as hyperphagia, in later childhood. PWS 
patients exhibit hypogonadism, have small hands and feet, and are short in stature if not 
subjected to growth hormone therapy. A large proportion of affected individuals display 
mood and behavioral disorders, such as temper tantrums and obsessive-compulsive 
disorder (Cassidy and Driscoll, 2009). PWS is caused by the loss of paternal expression 
from the imprinted domain of chromosome 15q11-q13.1. By overlapping atypical 
microdeletions carried by rare PWS patients, the critical region has been narrowed 
down to a 91 kb stretch of DNA that encodes for SNORD116 snoRNA cluster and a 
non-coding RNA, Imprinted in Prader-Willi (IPW) (Bieth et al., 2015). Functions of these 
RNA transcripts and the molecular pathway leading to PWS are still not well understood. 
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To date, there are only five reported cases of the aforementioned microdeletion patients 
(Anderlid et al., 2014; Bieth et al., 2015). Most PWS patients carry large deletions on the 
paternal allele of chromosome 15q11-q13.1 (70%). Maternal uniparental disomy (25%) 
and imprinting defects (5%) accounts for the rest of the PWS population (Cassidy and 
Driscoll, 2009). 
Dup 15q patients are present with hypotonia, epilepsy, and delayed motor and 
language development. Dup 15q patients are cognitively impaired and have learning 
disabilities. Affected individuals are often diagnosed with autism, accounting for 1-3% of 
total autistic population. In fact, copy number variation of chromosome 15q11-q13.1 is 
the most common chromosomal anomaly linked to autism (Cook et al., 1998; Schroer et 
al., 1998). Dup 15q can be caused by either an interstitial duplication (int dup(15)) of 
chromosome 15q11-q13.1 or a supernumerary isodicentric chromosome (idic(15)) 
formed by inverted duplication of proximal chromosome 15 (Battaglia, 2005). Although a 
molecular mechanism leading to Dup 15q is yet to be discovered, many genes within 
the duplicated region have been proposed to contribute to the disease etiology. Due to 
the fact that affected individuals often carry duplications of maternal origin or 
epigenotype, excessive UBE3A was proposed to be the primary cause of Dup 15q 
(Chamberlain and Lalande, 2010b). UBE3A, the gene disrupted in AS, is the only gene 
in the imprinted domain that is expressed exclusively from the maternal allele in brain. 
Furthermore, copy number across chromosome 15q11-q13.1 positively correlates with 
phenotype severity for Dup 15q syndrome, suggesting that there is a gene dosage 
effect (Schinzel et al., 1994). 
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In summary, AS, PWS, and Dup 15q syndrome are three clinically distinct 
neurodevelopmental disorders that are caused by mutations at chromosome 15q11-
q13.1. Due to genomic imprinting, the parental origin of mutation at chromosome 15q11-
q13.1 dictates the phenotype. It is clear that proper gene regulation at chromosome 
15q11-q13.1 on both maternal and paternal alleles is important for normal brain 
development. In Chapter 2, we developed modeling systems for AS, PWS, and Dup 15q 
syndrome by utilizing recently developed induced pluripotent stem cell (iPSC) 
technology. By studying all three disorders side by side, we hope to gain a holistic 
insight into the molecular mechanism of gene regulation at chromosome 15q11-q13.1. 
Our ultimate goal is to facilitate therapeutic development for these patients. In the 
following sections, I will discuss genomic imprinting at chromosome 15q11-q13.1 and 
the current view on how genes are regulated in this region during neural differentiation, 
including UBE3A and a long non-coding antisense transcript, UBE3A-ATS. 
1.3 Genomic Imprinting 
Humans possess two copies of each autosome, one from the mother and one 
from the father. Most autosomal genes are expressed bi-allelically, with equal 
contributions from the paternal and maternal allele. In the past few decades, scientists 
have identified a subset of genes that are expressed mono-allelically in a parent-of-
origin-specific manner. Such mono-allelic expression is established by an epigenetic 
phenomenon, known as genomic imprinting.  
Genomic imprinting is an evolutionarily conserved gene regulatory mechanism 
and plays a vital role during development. The effect of imprinting may be global, as 
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evidenced by the silencing of paternal chromosomes in all somatic cells in a group of 
male mealybugs (Khosla et al., 2006). It can also be tissue- or developmental stage-
specific. For example, UBE3A is bi-allelically expressed in most human tissues except 
brain, where there is only maternal expression due to silencing of the paternal allele. 
Currently, more than one hundred mammalian genes are known to be regulated by 
genomic imprinting. With the use of detailed tissue-specific analysis, many more may be 
discovered (Gregg et al., 2010).  
Genomic Imprinting is established in the germ line and is traditionally associated 
with DNA methylation and chromatin modifications (Vu et al., 2004; Yamasaki et al., 
2005). However, the parent-of-origin-specific epigenetic marks acquired during 
gametogenesis do not explain how tissue-specific imprinting is achieved, as these 
marks are present in all somatic cells to distinguish the two parental alleles from one 
another. This indicates that tissue-specific imprinted expression requires secondary 
imprinting regulators during cell differentiation to establish tissue-specificity, and these 
regulators depend on the existing parent-of-origin-specific marks to achieve allele-
specificity (Kishino, 2006). In addition to secondary DNA methylation and chromatin 
modifications, previous studies have implicated transcription and long non-coding 
antisense transcripts in regulating imprinting acquisition (Chotalia et al., 2009; Yamasaki 
et al., 2003). Given that the known genomic imprinting mechanisms cannot explain all 
incidences of imprinting-related disorders, there are likely other pathways yet to be 
identified (Buiting et al., 2003).  
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1.4 Regulation of Imprinted Genes at Chromosome 15q11-q13.1 
At human chromosome 15q11-q13.1, genomic imprinting regulates several 
genes that cluster in an imprinted domain (Figure 1). We focus on a small stretch of 
genes in the imprinted domain, from SNURF/SNRPN to UBE3A, which is important for 
gene regulation at this locus. Most genes in this region, including SNURF/SNRPN, 
SNORD116, IPW, SNORD115, and UBE3A-ATS, are expressed exclusively from the 
paternal allele. The coding portion of SNURF/SNRPN, SNORD116, and IPW are 
ubiquitously expressed, while the downstream SNORD115 and UBE3A-ATS exhibit 
neuron-specific expression. UBE3A and ATP10A are the only two maternally expressed 
genes in this region in brain. However, ATP10A may not be imprinted in all individuals 
(Hogart et al., 2008). UBE3A is biallelically expressed in most human tissues, while the 
paternal allele shuts down in brain, resulting in maternal-specific UBE3A expression. 
The imprinted gene expressions mentioned above are controlled by two factors—a 
bipartite imprinting center (Reis et al., 1994; Saitoh et al., 1996) and a long non-coding 
antisense RNA (Landers et al., 2004; Rougeulle et al., 1998)—as described below. 
 
1.4.1 Bipartite Imprinting Center 
Genes residing in the imprinted domain of chromosome 15q11-q13.1 are 
regulated by a bipartite imprinting center, which includes a Prader-Willi syndrome 
imprinting center (PWS-IC) and an Angelman syndrome imprinting center (AS-IC) 
(Saitoh et al., 1996). PWS-IC encompasses the first exon of SNURF/SNRPN and 
a differentially methylated region (DMR). AS-IC represses the activity of PWS-IC 
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when establishing parent-of-origin-specific epigenetic marks in the maternal germ 
line. This repression results in DNA methylation on the maternal DMR and 
silencing of paternal-specific genes on the maternal allele in daughter somatic 
cells. On the other hand, the paternal DMR remain unmethylated, which allows 
paternal-specific expression of SNURF/SNRPN and its downstream transcripts, 
including SNORD116, IPW, and SNORD115. For these transcripts, PWS-IC 
functions as a canonical promoter, but PWS-IC also acts as an enhancer element 
for the proximal paternally expressed genes (Rodriguez-Jato et al., 2005). 
 
1.4.2 Long Non-coding Antisense RNA—UBE3A-ATS 
Paternally expressed SNURF/SNRPN and its downstream transcripts are 
transcribed as a single long non-coding RNA, which goes through extensive and 
complicated splicing events to produce two protein-coding transcripts and a 
variety of long and short noncoding RNAs (Runte et al., 2001). In most human 
tissues, this long RNA transcript starts at SNURF/SNRPN, encompasses 
SNORD116, and stops at IPW. In neurons, transcription continues through IPW, 
produces downstream non-coding transcripts, including SNORD115, and 
encompasses almost the entire region antisense to UBE3A. This neuron-specific 
long non-coding antisense RNA, known as UBE3A-ATS, is thought to 
epigenetically control the imprinted expression of UBE3A in brain, although the 
precise mechanism is not known (Landers et al., 2004; Rougeulle et al., 1998). 
Its paternal-specific expression is controlled by the DMR in PWS-IC. When the 
AS-IC, a repressor of the PWS-IC, is perturbed, the maternal allele assumes a 
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paternal epigenotype and results in AS (Buiting et al., 1999; Saitoh et al., 1996). 
This is presumably due to the aberrant maternal UBE3A-ATS expression in 
neurons that silences UBE3A on the maternal allele. Furthermore, when active 
transcription of UBE3A-ATS is disrupted, the dormant paternal UBE3A allele 
becomes un-silenced in neurons (Huang et al., 2012; Meng et al., 2015). 
 
It remains perplexing how the regulatory UBE3A-ATS is expressed in a tissue-
specific fashion, since the same specificity does not apply to the upstream 
SNURF/SNRPN coding transcripts, SNORD116, and IPW. One possibility is that tissue-
specific alternative promoters, instead of the canonical SNURF/SNRPN promoter at 
exon 1, may be utilized in neurons to produce neuron-specific transcripts that 
encompass UBE3A-ATS. Indeed, several alternative neuron-specific exons upstream of 
SNURF/SNRPN that are spliced to UBE3A-ATS have been characterized previously in 
a murine model (Landers et al., 2004). Another possibility is that tissue-specific 
alternative splicing regulators may alter the splicing pattern at this region and result in 
neuron-specific splicing products that include UBE3A-ATS. As discussed in Chapter 4, 
we identified splicing factors that were enriched in SNURF/SNRPN lncRNA binding but 
did not contribute to its regulation/expression.  
The mechanism through which UBE3A-ATS silences UBE3A on the paternal 
allele is also largely unknown. It was proposed that UBE3A-ATS may alter UBE3A 
promoter activity in cis and, hence, lead to UBE3A repression (Landers et al., 2004). 
However, this is unlikely because paternal UBE3A promoter was found to be 
hypomethylated and lack allele-specific histone modifications in brain (Kishino, 2006; 
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Makedonski et al., 2005). One of the most widely accepted hypotheses is that active 
UBE3A-ATS transcription blocks UBE3A transcription through steric hindrance between 
colliding RNA polymerase complexes (Shibata and Lee, 2003). Other mechanisms 
involving extensive sense-antisense overlap, such as RNA-hybridization in cis, are not 
excluded (Shibata and Lee, 2003). 
1.5 The Angelman Syndrome Gene—UBE3A 
As mentioned previously, UBE3A is the only gene in the imprinted domain that is 
expressed exclusively from the maternal allele in brain. Loss of maternal UBE3A results 
in Angelman syndrome, while excessive UBE3A was proposed to be the primary cause 
of Dup 15q syndrome. In brain, UBE3A imprinting only occurs in mature neurons, as 
UBE3A is biallelically expressed in neural precursors and glial cells (Dindot et al., 2008; 
Judson et al., 2014; Yamasaki et al., 2003). Maternal UBE3A protein expression is 
upregulated in mature neurons, presumably to compensate for the loss of paternal 
expression due to genomic imprinting (Dindot et al., 2008). UBE3A protein level is also 
regulated in an activity dependent manner—neuronal depolarization and fear 
conditioning lead to an increase in UBE3A protein in vitro and in vivo, respectively 
(Filonova et al., 2014). As neurons mature, UBE3A protein subcellular localization 
changes from cytoplasmic to nuclear (Judson et al., 2014; Miao et al., 2013). 
Interestingly, UBE3A protein level decreases during normal aging in mammalian and 
human postmortem brains (Williams et al., 2010b). Changes in UBE3A protein 
expression and localization during neuronal maturation and aging suggest that UBE3A 
may play different roles in developing and adult brain (Sell and Margolis, 2015). Indeed, 
recent studies showed that Ube3a restoration in adulthood was not sufficient to rescue 
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all neurological phenotypes in murine AS models (Meng et al., 2015; Silva-Santos et al., 
2015). Prenatal reinstatement of Ube3a, on the other hand, successfully reversed all 
AS-relevant phenotypes (Silva-Santos et al., 2015). Due to the fact that a prolonged 
period of time is required for human brain development, the critical window for 
therapeutic intervention is likely to be much longer in AS patients. To determine the 
timing of paternal UBE3A silencing in human, we attempted to create a UBE3A-GFP 
fusion reporter using AS iPSCs through CRISPR/Cas9-mediated gene editing, as 
described in Chapter 3. However, we were unable to detect abundant UBE3A-GFP 
fusion proteins in these cells, most likely caused by low expression or instability at the 
protein level. Nevertheless, a successful UBE3A-GFP reporter AS iPSC line would be 
informative on spatiotemporal regulation of UBE3A expression during human 
neurodevelopment as well as a useful tool for high throughput drug screening for AS 
treatments. 
Like most genes, UBE3A is subjected to alternative splicing and/or 
polyadenylation. It gives rise to five different RNA transcripts and is predicted to encode 
three different UBE3A protein isoforms in human (Yamamoto et al., 1997). In mouse, 
three Ube3a transcripts have been identified. Of these three Ube3a transcripts, isoform 
2 has the longest open reading frame, encoding for an 870 aa protein isoform. 
Compared to isoform 2, the protein product of isoform 3 lacks 21 aa on the N-terminus, 
while the protein product of isoform 1 lacks 21 aa on the N-terminus as well as 87 aa on 
the C-terminus (Miao et al., 2013). The shortened C-terminus encoded by isoform 1 
renders its protein product catalytically inactive (Valluy et al., 2015). In human, the fifth 
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UBE3A RNA transcript undergoes alternative polyadenylation and corresponds to the 
murine Ube3a isoform 1 (Valluy et al., 2015). The unique 3’-UTR of Ube3a isoform 1 
mRNA regulates dendrite complexity and spine morphogenesis by acting as a sponge 
and sequestering regulatory microRNAs in rats (Valluy et al., 2015). On the other hand, 
catalytically active Ube3a proteins from isoform 2/3 are important for polarized dendrite 
morphogenesis in mouse pyramidal neurons through dendritic Golgi deployment (Miao 
et al., 2013). In addition, when overexpressed in mouse brain, Ube3a isoform 1 and 2 
are largely cytosolic, while isoform 3 mostly localizes to the nucleus (Miao et al., 2013). 
These findings in murine models suggest that each UBE3A isoforms may have its 
unique role in brain development. 
UBE3A encodes for an ubiquitin protein ligase E3A, also known as E6-AP. E6-
AP is one of the E3 ubiquitin ligases, which are important for protein degradation 
through proteasome by tagging poly-ubiquitin chains to its targets (Huang et al., 1999; 
Scheffner et al., 1993). Recently, it was reported that catalytically active E6-AP 
functions as an oligomer (Ronchi et al., 2014). Since mutations or short in-frame 
deletions that render E6-AP catalytic domain nonfunctional have been reported in AS 
patients, improper regulation and accumulation of E6-AP substrate(s) was proposed to 
be the major cause for AS (Cooper et al., 2004). On the other hand, excessive E6-AP is 
hypothesized to cause accelerated protein degradation and reduced substrate level in 
Dup 15q syndrome. In the past few years, identifying disease-relevant substrates for 
E6-AP has been one of the major focuses in the field, although few of them have been 
reported, including Pbl/ECT2 (Reiter et al., 2006), Ephexin5 (Margolis et al., 2010), Arc 
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(Greer et al., 2010), and GAT1 (Egawa et al., 2012). Whether Arc is a direct substrate of 
E6-AP is still debatable (Kuhnle et al., 2013; Mabb et al., 2014). In addition to protein 
ubiquitination, E6-AP has been reported as a transcriptional coactivator, although this 
function is not associated with central AS phenotypes (Nawaz et al., 1999; Smith et al., 
2002). Other secondary changes in protein level or activity caused by the loss of E6-AP 
were also reported, such as Na+/K+-ATPase α1 subunit (Kaphzan et al., 2013) and 
hippocampal CaMKII phosphorylation (van Woerden et al., 2007; Weeber et al., 2003). 
By modulating downstream targets of E6-AP, some AS characteristic phenotypes can 
be rescued in murine models (Egawa et al., 2012; Kaphzan et al., 2013; Mandel-Brehm 
et al., 2015; van Woerden et al., 2007). However, not a single target alone can fully 
reverse the effect of E6-AP loss in AS neurons, indicating that AS is likely caused by 
alterations of a complicated gene and protein network (Sell and Margolis, 2015).  
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Figure 1. Human chromosome 15q11-q13.1 imprinted cluster at UBE3A locus. 
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Chapter 2 
Disease Modeling Using Induced Pluripotent Stem Cells for Angelman, Prader-
Willi, and Dup 15q Syndromes 
 
 
 
Data presented in this chapter are published in the following papers: 
 
Chamberlain, S.J., Chen, P.F., Ng, K.Y., Bourgois-Rocha, F., Lemtiri-Chlieh, F., Levine, 
E.S., and Lalande, M. (2010). Induced pluripotent stem cell models of the genomic 
imprinting disorders Angelman and Prader-Willi syndromes. Proc Natl Acad Sci U S A 
107, 17668-17673. 
My Contribution: iPSC characterization, methylation-specific RT-qPCR, RT-PCR 
Germain, N.D., Chen, P.F., Plocik, A.M., Glatt-Deeley, H., Brown, J., Fink, J.J., Bolduc, 
K.A., Robinson, T.M., Levie, E.S., Reiter, L.T., et al. (2014). Gene expression analysis 
of human induced pluripotent stem cell-derived neurons carrying copy number variants 
of chromosome 15q11-q13.1. Molecular autism 5, 44. 
My Contribution: neural differentiation, methylation-specific RT-qPCR 
Martins-Taylor, K., Hsiao, J.S., Chen, P.F., Glatt-Deeley, H., De Smith, A.J., Blakemore, 
A.I., Lalande, M., and Chamberlain, S.J. (2014). Imprinted expression of UBE3A in non-
neuronal cells from a Prader-Willi syndrome patient with an atypical deletion. Hum Mol 
Genet 23, 2364-2373. 
License Date: Jan 29, 2016; License Number: 3798290102999 
My Contribution: methylation-specific RT-qPCR, RT-qPCR 
Chamberlain, S.J., Germain, N.D., Chen, P.F., Hsiao, J.S., and Glatt-Deeley, H. (2016). 
Modeling Genomic Imprinting Disorders Using Induced Pluripotent Stem Cells. Methods 
Mol Biol 1353, 45-64. 
License Date: Jan 10, 2016; License Number: 3785350330106 
My Contribution: manuscript writing for allele-specific PCR and proof reading.  
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2.1 Background and Significance 
Murine models have provided significant insights on AS, PWS, and Dup 15q 
syndrome because they are more amenable genetically than human cells and they 
provide neurons developed in natural context as well as behavioral phenotypes. Murine 
models were especially instrumental in understanding imprinting regulatory mechanism 
at AS- and PWS-IC (Chamberlain and Brannan, 2001; Johnstone et al., 2006; Yang et 
al., 1998), as well as ruling out genes that are not central to disease phenotypes 
(Bischof et al., 2007; Mercer and Wevrick, 2009; Tsai et al., 1999a; Tsai et al., 1999b). 
However, cognitive and social impairments in non-primates are hard to assess, and 
current AS, PWS, and Dup 15q murine models failed to fully recapitulate human 
phenotypes. The divergence in gene regulation between mouse and human at the 
homologous region to human chromosome 15q11-q13.1 may explain the phenotypic 
differences (Chamberlain and Lalande, 2010b). In mice, the entire SNURF/SNRPN 
lncRNA that silences paternal UBE3A is only expressed in neurons, while only the 
second half of SNURF/SNRPN lncRNA (i.e. from SNORD115 to UBE3A-ATS) is 
neuron-specific in human.  
The most relevant tissue, fetal brain, for rare neurodevelopmental disorders, such 
as AS, PWS, and Dup 15q syndromes, has been difficult to obtain and limited to post-
mortem samples with varying qualities. Ever since Thomson et al. established the first 
human embryonic stem cell line in 1998, scientists have been looking for ways to obtain 
live human neurons through in vitro neural differentiation. The first neural differentiation 
protocol using human embryonic stem cells was established in 2001 (Zhang et al., 
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2001), and many more refined protocols for specific neuronal subtype soon followed 
(Germain et al., 2013; Li et al., 2008; Perrier et al., 2004). In 2007, Takahashi et al. 
made a Nobel-winning discovery, namely induced pluripotent stem cell (iPSC) 
technology, which enables scientists to convert human somatic cells back to an 
embryonic stem cell-like stage (Takahashi et al., 2007). In combination, these two 
technologies revolutionized the field of neurological disease modeling, providing 
unlimited and readily accessible patient-derived neuronal tissues. 
To address the fundamental question of how imprinting at chromosome 15q11-
q13.1 is regulated in human brain, we established patient-derived iPSCs and their 
neural derivatives as models for AS, PWS, and Dup 15q syndrome (Chamberlain et al., 
2010; Germain et al., 2014; Martins-Taylor et al., 2014). Specifically, we took advantage 
of large deletions that cause AS and PWS to study paternal- and maternal-specific gene 
expression respectively. With this system, we were able to study the gene regulatory 
mechanism at chromosome 15q11-q13.1 in an allele-specific manner (manuscript under 
review and (Cruvinel et al., 2014)). A rare microdeletion from a PWS patient provided us 
insights on the regulation of neuron-specific portion of the SNURF/SNRPN lncRNA 
(Martins-Taylor et al., 2014). In addition, cells with various chromosome 15q11-q13.1 
duplications helped decipher gene contributions to Dup 15q syndrome (Germain et al., 
2014). In this chapter, I will discuss the process of reprogramming, iPSC quality control, 
techniques used to determine the imprinting status at chromosome 15q11-q13.1, and 
neural differentiation. 
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2.2 Rationale 
Given the differences in phenotypes and SNURF/SNRPN lncRNA tissue-
specificity between mice and patients with AS, PWS, and Dup 15q syndrome, patient-
derived iPSCs and their neural derivatives can provide insights on gene regulation at 
chromosome 15q11-q13.1 during human neurodevelopment. These cells are also useful 
for identifying potential therapeutic targets and drug screening. 
One concern for modeling human disorders involving genomic imprinting using 
iPSCs is that the parental imprints may be altered in the process of converting somatic 
cells to iPSCs (Colman and Dreesen, 2009; Pick et al., 2009). It is known that 
chromosome modifications and DNA methylation, which are responsible for genomic 
imprinting, can be erased and re-established at certain loci during reprogramming 
(Colman and Dreesen, 2009; Pick et al., 2009; Takahashi et al., 2007). However, we do 
not expect these changes to occur at the PWS-IC because the chromosome 
modifications and DNA methylation at this locus are established in the male and female 
germlines, instead of early embryos (Buiting et al., 1995; Dittrich et al., 1996; Ferguson-
Smith, 1996). Moreover, DNA methylation at PWS-IC is stably maintained in mouse as 
well as human embryonic stem cells (Rugg-Gunn et al., 2007; Schumacher and Doerfler, 
2004). 
To determine whether patient-derived iPSCs and their neural derivatives can be 
used as a proper disease models for AS, PWS, and Dup 15q syndrome, we carefully 
assessed the methylation status at PWS-IC and gene expression at chromosome 
15q11-q13.1. We measured neuronal activities using electrophysiology and determined 
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neural cell types using immunocytochemistry to ensure that these neurons are 
functional and that the neural culture mimics cortical population. We also assessed 
UBE3A imprinting status by measuring UBE3A protein level with Western blotting as 
well as UBE3A-ATS expression using RT-PCR, allele-specific PCR, and RNA 
fluorescence in situ hybridization (RNA-FISH). 
2.3 Materials and Methods 
iPSC Cell Culture 
All iPSCs used in this study were maintained as described before (Chamberlain 
et al., 2010). Briefly, iPSCs were grown on irradiated mouse embryonic 
fibroblasts (iMEFs) and fed daily with conventional hESC medium consisting of 
DMEM-F12 supplemented with knock-out serum replacer, nonessential amino 
acids, L-glutamine, β-mercaptoethanol, and basic FGF. iPSCs were cultured in a 
humid incubator at 37 °C with 5% CO2 and passaged approximately once a week 
manually. 
Methylation-Specific PCR 
Genomic DNAs were subjected to bisulfite conversion using the EZ DNA 
methylation-Gold Kit (Zymo Research) according to the manufacturer’s 
instructions. A multiplex PCR was carried out using the following primers:  
15maternalF, 5′-TAATAAGTACGTTTGCGCGGTC-3′; 
15maternalR, 5′-AACCTTACCCGCTCCATCGCG-3′; 
15paternalF, 5′-GTAGGTTGGTGTGTATGTTTAGGT-3′; 
15paternalR, 5′-ACATCAAACATCTCCAACAACCA-3′. 
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Quantitative Reverse-Transcription PCR 
RNA samples were isolated using RNA-Bee (Tel-Test Inc.) and converted into 
cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
according to the manufacturer’s instructions.!Expression levels of target genes 
were measured using Taqman gene expression assays (Applied Biosystems) 
following the manufacturer’s protocol. All genes were normalized to GAPDH. 
Relative quantity (RQ) value was calculated as 2^-ΔΔCt using the calibrator 
sample. 
Neural Differentiation 
iPSC-derived neuronal culture were generated using either embryoid-body based 
(Pankratz et al., 2007) or monolayer (Germain et al., 2013) differentiation 
protocol with some modifications as previously reported (Chamberlain et al., 
2010; Germain et al., 2014). Briefly, iPSC colonies were manually cut and lifted 
when generating embryoid bodies for the embryoid-body protocol. After three 
weeks of neural differentiation using either protocol, neural progenitors were 
plated on tissue culture plates coated with poly-ornithine/laminin. The neural 
differentiation medium consisted of Neurobasal Medium, B-27 supplement, 
nonessential amino acids, and L-glutamine, and was supplemented with 1 μM 
ascorbic acid, 200 μM cyclic adenosine monophosphate, 10 ng/mL brain-derived 
neurotrophic factor, and 10 ng/mL glial-derived neurotrophic factor. Unless 
otherwise specified, all experiments were conducted on neural cultures that were 
at least 10 weeks old. 
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Immunocytochemistry 
Immunocytochemistry was carried out as previously described (Chamberlain et 
al., 2010; Germain et al., 2014). The following antibodies and concentrations 
were used: rabbit anti-NANOG (1:100, Abcam), mouse anti-SSEA4 (1:20, 
Developmental Studies Hybridoma Bank), mouse anti-TRA1-60 (1:200, Santa 
Cruz), mouse anti-TRA1-81 (1:200, Santa Cruz), mouse anti-PAX6 (1:20, 
Developmental Studies Hybridoma Bank), rabbit anti-MAP2 (1:200, Millipore), 
chicken anti-MAP2 (1:10,000, Abcam) mouse anti-TUJ1 (1:200, Covance), rabbit 
anti-SynapsinI (1:200, Millipore), mouse anti-PSD-95 (1:100, NeuroMab), mouse 
anti-PanNav (1:200, Sigma), rabbit anti-S100β (1:200, Abcam), mouse anti-
VGLUT1 (1:100, Synaptic Systems), and rabbit anti-GAD65/67 (1:2000, Sigma). 
AlexaFluor goat anti-rabbit and anti-mouse 488, 594, and 647 fluorochrome 
conjugated secondary antibodies (Life Technology) were used at 1:200. A goat 
anti-chicken IgY-650 secondary antibody (Abcam) was used at 1:250. Nuclei 
were counterstained with DAPI and coverslips were mounted on slides with 
Vectashield (Vector Laboratories). Slides were imaged using a Zeiss Axiovision 
microscope at magnification of 5X, 20X, 40X, and 63X.  
DNA Methylation Analysis, Allele-specific PCR, and RNA Fluorescence in situ 
Hybridization (RNA FISH) 
Detailed protocols (Chamberlain et al., 2016) are published in a book, titled 
“Patient-specific Induced Pluripotent Stem Cell Models,” shown as following. 
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2.4 Methods Section for DNA Methylation Analysis, Allele-specific PCR, and RNA 
Fluorescence in situ Hybridization 
Licensee: Pin-Fang Chen  
License Date: Jan 10, 2016  
License Number: 3785350330106  
Publication: Springer eBook  
Title: Modeling Genomic Imprinting Disorders Using Induced Pluripotent Stem Cells 
Type Of Use: Thesis/Dissertation  
 
Modeling Genomic Imprinting Disorders Using Induced Pluripotent Stem Cells 
 
Chamberlain, S.J., Germain, N.D., Chen, P.F., Hsiao, J.S., and Glatt-Deeley, H. (2016). 
Modeling Genomic Imprinting Disorders Using Induced Pluripotent Stem Cells. Methods Mol 
Biol 1353, 45-64. 
 
i.    Abstract 
Induced pluripotent stem cell (iPSC) technology has allowed for the invaluable modeling of 
many genetic disorders including disorders associated with genomic imprinting. Genomic 
imprinting involves differential DNA and histone methylation and results in allele-specific gene 
expression. Most of the epigenetic marks in somatic cells are erased and reestablished during the 
process of reprogramming into iPSCs. Therefore, in generating models of disorders associated 
with genomic imprinting, it is important to verify that the imprinting status and allele-specific 
gene expression patterns of the parental somatic cells is maintained in their derivative iPSCs. 
Here, we describe three techniques: DNA methylation analysis, allele-specific PCR, and RNA 
FISH, that we use to analyze genomic imprinting in iPSC models of neurogenetic disorders 
involving copy number variations of the chromosome 15q11-q13 region.   
 
ii.   Keywords 
induced pluripotent stem cells, genomic imprinting, DNA methylation, allele-specific PCR, RNA 
FISH 
 
1. Introduction 
Genomic imprinting is an epigenetic phenomenon by which genes are expressed in a parent-of-
origin dependent manner.  This process occurs primarily in eutherian mammals, although it can 
also be observed in plants and metatherians.  The estimated number of imprinted genes varies 
from a conservative estimate of 100 genes(Henckel and Arnaud, 2010) to more than 1,000(Gregg 
et al., 2010), depending on how such imprinted expression was ascertained and the criteria for 
determining whether a gene is imprinted(Kelsey and Bartolomei, 2012).   
 
DNA cytosine methylation, as well as specific active and repressive histone modifications are 
involved in mediating the allele-specific gene expression in genes regulated by genomic 
imprinting.  Most imprinted loci have an imprinting control region (ICR) that is an area of 
differential DNA methylation between the two parental alleles(Henckel and Arnaud, 2010).  The 
ICR is typically methylated on the silent, repressed allele and unmethylated on the expressed, 
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active allele.   Repressive histone modifications, such as trimethylation of  histone H3 on lysine 9 
(H3K9me3) and histone H3 lysine 79 (H3K79me3) often accompanies DNA methylation on the 
repressed allele of the ICR(Singh et al., 2011).  Active histone modifications such as di- and 
trimethylation of histone H3 on lysine 4 (H3K4me2 and me3), mono-and dimethylation of 
histone H3 lysine 79 (H3K79me1 and me2), and acetylation at histone H4 lysine 91 (H4K91Ac) 
often adorn the unmethylated allele at the ICR(Singh et al., 2011).  Altogether, the ICR often 
controls the imprinted expression of all of the genes within the imprinted cluster, regardless of 
the parent of origin of their gene expression.  Thus, the ICR harbors important epigenetic 
modifications that ultimately determine the allele-specific expression of several imprinted genes 
within a cluster.   
 
Imprinted genes, which are expressed from a single parental allele, are functionally haploid in 
the organism.  Deletion or mutation of the single expressed allele leaves an organism null for the 
imprinted gene.  Several human neurogenetic disorders arise from the disruption of the expressed 
alleles of imprinted genes.  Prader-Willi and Angelman syndromes are caused by the loss of 
function from paternally- and maternally-inherited alleles of the chromosome 15q11-13 region, 
respectively(Chamberlain and Lalande, 2010a).  Beckwith-Wiedemann syndrome is caused by 
the loss of function from maternal chromosome 11p15(Jacob et al., 2013).  Silver-Russell 
syndrome is caused by disruption of imprinted genes on chromosomes 7(Nakabayashi et al., 
2002) and 11(Jacob et al., 2013).  Pseudohypoparathyroidism (Albright’s hereditary 
osteodystrophy) and uniparental disomy 14 are also disorders caused by disruption of imprinted 
genes(Davies and Hughes, 1993).  Complex genetic regulation underlies the imprinted genes in 
each of these disorders, making it difficult to generate cell culture or animal models.   
 
Human induced pluripotent stem cells (iPSCs) are becoming an attractive approach to modeling 
complex genetic disorders, such as those involving genomic imprinting(Chamberlain et al., 
2008).  The use of somatic cells derived from patients enables the genetic complexities to be 
captured in indefinitely self-renewing stem cells that are capable of differentiation into virtually 
any lineage.   Using iPSC technology, copy number variation and uniparental disomy that often 
leads to disorders involving genomic imprinting can be recapitulated in stem cells.  Our group 
has generated iPSCs from individuals with Prader-Willi syndrome, Angelman syndrome, and 
Dup15q syndrome, which all involve copy number variation at an imprinted locus(Chamberlain 
et al., 2010; Germain ND, 2014; Martins-Taylor et al., 2014).  However, epigenetic 
modifications are erased and established during the reprogramming process involved in the 
establishment of iPSC lines.   Since appropriate expression of imprinted genes depends on the 
maintenance of epigenetic modifications during the reprogramming process, extensive analysis 
of the relevant epigenetic modifications and gene expression is a stringent requirement for 
modeling disorders that involve genomic imprinting.  Here we detail methods that our lab uses to 
verify appropriate imprinted expression of genes at the human chromosome 15q11-13 locus.    
 
Differential DNA methylation at the ICR underlies virtually every genomic imprint.  We use a 
quantitative PCR (qPCR) based assay to quantify the fraction of methylated and unmethylated 
alleles at the human Prader-Willi syndrome imprinting center (PWS-IC).   This assay is excellent 
for quantifying cytosine methylation at ICRs that are relatively stable.  It can assay up to seven 
CpG dinucleotides, but it cannot assay the CpGs individually.  In contrast to other protocols for 
methylation specific PCR, this approach does not require bisulfite conversion to assay 
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methylation at specific CpGs.  Rather, it relies on the digestion of DNA by methylation sensitive 
and methylation dependent restriction enzymes followed by quantification of the DNA by qPCR 
(Bruce et al., 2008; Oakes et al., 2006; Yamada et al., 2004).  The methylation sensitive enzymes 
(MSREs) used can only cleave unmethylated DNA since methylated cytosines block enzyme 
activity.  In contrast, methylation dependent restriction enzymes (MDREs) will only digest DNA 
at methylated cytosine residues.  Therefore, digestion with MSREs leaves only methylated DNA 
and digestion with MDREs leaves only unmethylated DNA available for PCR amplification.  
Using primer sets designed to flank the specific DNA region of interest, the digested DNA is 
then analyzed by qPCR.  By comparing the cycle threshold (Ct) values generated for each of the 
digest conditions, the relative amounts of methylated and unmethylated DNA in the region is 
calculated.  Two control reactions are included to allow for more accurate quantitation.  A mock 
digest is performed without either enzyme to quantify the amount of total input DNA amplified 
with the chosen primer set.  A double digest, including both the MSREs and the MDREs, 
represents background signal from the qPCR reaction as all of the DNA should be digested and 
unavailable for amplification.  
 
The actual expression of imprinted genes is the single most important factor in determining 
whether the genomic imprint is correctly established in iPSCs.  The collection of epigenetic 
modifications amalgamates in a precise parent-of-origin gene expression pattern for each 
imprinted gene.   We use allele-specific PCR and/or RNA fluorescence in situ hybridization 
(RNA-FISH) to determine allele specific gene expression.  The allele-specific PCR assay can 
correctly ascribe gene expression to a single parental allele.  This can be used to ascertain the 
allele-specificity across a population of cells.  This assay takes advantage of polymorphic 
sequences on each allele to distinguish the origin of sense and anti-sense RNA transcripts 
expressed from the same genomic locus. The first step in this approach is to identify existing 
polymorphism in the target gene. Once the polymorphism is verified, strand-specific reverse 
transcription is used to distinguish sense and anti-sense transcripts. Followed by PCR 
amplification across the verified polymorphism, the origin of sense and anti-sense transcripts can 
be deciphered. RNA-FISH, on the other hand allows one to assay sense versus antisense 
transcription, which often accompanies imprinted gene expression, on a cell-by-cell basis. 
 
2. Materials 
 
2.1 DNA Methylation Analysis Components 
1. Cell lysis buffer: 0.5% Sarcosyl, 200nM NaCl, 10mM EDTA, 10mM Tris pH 8.0 
2. Proteinase K (20mg/mL, catalog #P8107S, New England Biolabs) 
3. Cell scrapers 
4. 1.5mL Eppendorf tubes 
5. Phenol-chloroform with isoamyl alcohol 
6. 100% ethanol 
7. DNase-free distilled water (dH20) 
8. Microcentrifuge 
9. NanoDrop spectrophotometer 
10. EpiTect Methyl II DNA Restriction Kit (catalog #335452, SABiosciences) or individual 
MSREs / MDREs (e.g., MspI, HpaII, etc., New England Biolabs) 
11. 0.2mL PCR microtube strips with caps 
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12. Thermocycler 
13. EpiTect Methyl PCR Primer Assay for the gene of interest.  For the PWS-IC, we use a 
human SNRPN primer (catalog #EPHS104317-1A, SABiosciences).  Alternatively, 
primer sets can be designed that flank the methylation sites to be analyzed using various 
software programs and ordered from commercial providers.  
14. SYBR-Green PCR Master Mix (catalog #330520, SABiosciences or catalog  #4334973, 
Applied Biosystems) 
15. 96-well PCR plates 
16. Tabletop centrifuge 
17. Quantitative PCR instrument 
 
2.2 Allele-specific PCR Components 
1. Primers for amplifying polymorphic sequence 
2. Phusion® High-Fidelity DNA Polymerase (catalog #M0530S, New England Biolabs) 
3. QIAquick PCR Purification Kit (catalog #28104, Qiagen) 
4. T7 Endonuclease I (catalog #M0302S, New England Biolabs) 
5. Gel electrophoresis apparatus, 2% agarose gel, and matching buffer 
6. RNA-Bee (catalog # #CS-104B, Tel Test, Inc.) 
7. TURBO DNA-free Kit (catalog #AM1907, Life Technologies) 
8. Superscript III (catalog #18080044, Life Technologies) 
9. Tagged RT primers (S-RT and ATS-RT) 
10. Advantage 2 Polymerase Mix (catalog #639207, Clontech) 
11. PCR primers for tag sequences (F’ and R’) 
12. PCR forward and reverse primers (F and R) 
13. Novex TBE 6% polyacrylamide gel (catalog #EC6265BOX, Life Technologies) 
14. TBE Buffer (catalog #15581-044, Life Technologies) 
15. XCell SureLockTM Mini-Cell (catalog #EI0001, Life Technologies) 
16. SYBR Gold (catalog #S-11494, Life Technologies) 
 
2.3 RNA FISH Components 
1. 12 mm round coverslips (catalog #12-545-80, Fisherbrand) 
2. Nick Translation DNA Labeling System (catalog #ENZ-42910, Enzo) 
3. ChromaTide Alexa Fluor 594-5-dUTP (catalog #C-11400, Life Technologies) 
4. SNORD115 BAC  (RP11-37A4, CHORI) 
5. MAXIscript T7/T3 Kit (catalog #AM-1324M, Life Technologies) 
6. ChromaTide Alexa 488-5-UTP (catalog #C-11403, Life Technologies) 
7. Not I (catalog #R0189L, New England Biolabs) 
8. Carbonate buffer: 60 mM Na2CO3 and 40 mM NaHCO3 
9. Micro Bio-Spin P-30 Tris column (catalog #732-6223, Bio-Rad) 
10. Human Cot-I DNA 1 µg/µL (catalog #1 581 074, Roche) 
11. Salmon sperm DNA 
12. 20X SSC (Various SSC dilutions, including 4X SSC, 2X SSC, and 1X SSC, are made 
from this 20X SSC stock.) 
13. 2X hybridization buffer: 1 part 20X SSC, 1 part 10 mg/mL BSA, 1 part nuclease-free 
water, and 2 parts 50% dextran sulfate. 
14. CSK buffer: 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, and 10mM PIPES pH6.8. 
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15. 1% Triton X-100/CSK: 100 µL Triton X-100 in 9.9 mL CSK buffer 
16. 50% formamide/2X SSC: 1 part 100% formamide in 1 part 4X SSC 
17. Vectashield with DAPI (catalog #H-1200, Vector Laboratories) 
 
3. Methods 
3.1 DNA methylation analysis 
 3.1.1 Isolate Genomic DNA 
1. Collect iPSCs (approximately 2x106 cells) by scraping with a cell scraper and pellet in a 
1.5mL Eppendorf tube. 
2. Add 300µL of Cell Lysis Buffer and 20µl of 20mg/mL Proteinase K to pelleted cells.  
Vortex and incubate in a 55˚C waterbath overnight (at least 18 hours). (See Note 1) 
3. Add 300µL of phenol-chloroform to lysate and vortex at least 30 seconds. 
4. Spin for 3 minutes at maximum speed in a room temperature microcentrifuge. 
5. Carefully transfer the upper aqueous phase to a new 1.5mL Eppendorf tube. Avoid 
contact with the lower phenol phase or the white interphase which may have formed after 
centrifugation. 
6. Add 1mL of 100% ethanol to aqueous phase and invert tube several times. White strands 
of DNA should be visible as it precipitates. 
7. Spin for 5 minutes at maximum speed in a room temperature microcentrifuge. 
8. Remove all supernatant and air dry pelleted DNA for approximately 5-10 minutes. 
9. Resuspend DNA in 50-100µL of dH20. 
10. Check concentration of DNA using a NanoDrop spectrophotometer.  
11. Store at 4˚C or at -20˚C for long term storage. 
 
3.1.2 Perform restriction digest with MSREs and MDREs 
1. Prepare a solution of 0.5-1.0µg of DNA with the appropriate dilution of restriction digest 
buffer and dH20. If using the EpiTect Methyl II DNA Restriction Kit, use 26µL of 5X 
Digestion Buffer and add dH20 to a final volume of 120µL. If using restriction enzymes 
from another source, prepare a volume of 200µL, which is sufficient for four 50µL 
individual restriction digest reactions. (See Note 2) 
2. Thoroughly mix the DNA/buffer solution and divide equally into four separate PCR tubes. 
(See Note 3)  
3. Set up the restriction digest reactions and controls by adding the following to each PCR 
tube: If using the EpiTect Methyl II DNA Restriction Kit, for MSRE reaction– add 1µL 
of dH20 and 1µL of MSRE (Enzyme A), for MDRE – add 1µL of dH20 and 1µL of 
MDRE (Enzyme B), for the double digest – add 1µL each of the MSRE and MDRE, and 
for the mock digest – add 2µL of dH20 in place of restriction enzymes. (See Note 4)  
4. Mix reactions gently by pipetting and briefly spin samples in a microcentrifuge. 
5. Incubate reactions at 37˚C in a thermocycler for at least 6 hours to overnight. 
6. Inactivate restriction enzymes by incubating reactions at 65˚C for 20 minutes in a 
thermocycler. 
7. Perform qPCR with digested DNA or store digest reactions at -20˚C until use. 
 
3.1.3 Analyze digested DNA by qPCR 
1. Prepare qPCR reaction master mix by combining SYBR-green qPCR Master Mix, 
EpiTect Methyl PCR Assay Primer, and dH20 sufficient to run each DNA sample in 
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triplicate (each mock, MSRE, MDRE, and MSRE+MDRE digest is considered a separate 
sample). To account for pipetting volume error, prepare enough master mix for at least 
two excess reactions. Each 20µL total PCR reaction will ultimately contain: 10µL 
SYBR-green qPCR Master Mix, 1µL EpiTect Methyl PCR Assay Primer, 5µL of digest 
DNA and 4µL dH20. (See Note 5) 
2. Pipette 15µL of master mix reaction into each well of the qPCR plate. Add 5µL of 
sample to the individual wells and mix my gentle pipetting.  
3. Seal the qPCR plate and spin briefly in a tabletop centrifuge. 
4. Perform qPCR amplification. If using EpiTect Methyl PCR Assay primers the following 
conditions should be used: (1) 95˚C for 10 minutes to activate HotStart DNA polymerase. 
(2) 3 cycles of 99˚C for 30 seconds and 72˚C for 1 minute. (3) 40 cycles of 97˚C for 15 
seconds and 72˚C for 1 minute. (4) Standard melting curve. Record SYBR-green signal at 
each of the 72˚C cycles in step 3. (See Note 6)  
5. Calculate percent methylated and percent unmethylated DNA using the Ct values 
generated from the qPCR run. SABiosciences provides an Excel spreadsheet which can 
be used to automatically perform these calculations after inserting the mean Ct value for 
each sample. This spreadsheet takes into account the percentage of DNA resistant to 
digestion (represented by the double digest reaction) in calculating the percent 
methylated and unmethylated DNA.  Alternatively, several methods have been 
independently reported to perform these calculations (See Note 7).   
 
3.2 Allele-specific PCR 
3.2.1 Screening for Polymorphic Sequence 
1. Use tracks under the categories of “Variation” or “Repeats” in UCSC Genome Browser 
(genome.ucsc.edu) to look for reported SNPs or short tandem repeats in the target gene. 
As an example, a polymorphic region of short tandem repeats in an intron of UBE3A 
gene was identified using the “Microsatellite” track in Figure 1.   
2. Carry out T7 E1 assay with the following steps modified from the manufacturer’s 
protocol for T7 Endonuclease I.  
i. Prepare good quality genomic DNA from cells as described in section 3.1.1 
(see Note 8). 
ii. Design primers to amplify about 1kb region around the polymorphic sequence, 
preferably with the polymorphic sequence offset from the center as shown in 
Figure 1 (see Note 9).  
iii. Carry out 50µL PCR reaction using Phusion® High-Fidelity DNA 
Polymerase or other proofreading DNA polymerase to obtain correct PCR 
product.  
iv. Clean up PCR product using QIAquick PCR Purification Kit and elute DNA 
in 30µL elution buffer. When eluting, let the column sit in elution buffer at 
room temperature for at least 5 minutes before spinning to increase yield. 
v. Measure DNA concentration using a NanoDrop spectrophotometer (see Note 
8). 
vi. Add 150ng of cleaned PCR product into a 0.2mL PCR tube. Add 1µL of 10x 
NEBuffer 2 and bring the total volume up to 10µL with water. Save the 
remaining PCR product as a control for gel electrophoresis in a later step. 
vii. Run the following program in a thermocycler to make heteroduplex: 
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95°C 10 minutes 
95°C to 85°C decrease 2.0°C per second 
85°C 1 minute 
85°C to 75°C decrease 0.3°C per second 
75°C 1 minute 
75°C to 65°C decrease 0.3°C per second 
65°C 1 minute 
65°C to 55°C decrease 0.3°C per second 
55°C 1 minute 
55°C to 45°C decrease 0.3°C per second 
45°C 1 minute 
45°C to 35°C decrease 0.3°C per second 
35°C 1 minute 
35°C to 25°C decrease 0.3°C per second 
25°C 1 minute 
4°C  
 
viii. Add 0.5µL of T7 Endonuclease I into the PCR tube and incubate at 37°C for 
30 minutes in a thermocycler to cut any heteroduplex that has formed in the 
previous step.  
ix. Stop the reaction by adding 2.5µL of loading dye that contains 0.1M EDTA 
(see Note 10). 
x. Run the digested product alongside the original PCR product from step vi on a 
2% agarose gel. As an example, a gel for a polymorphic sequence verified by 
T7 E1 assay is shown in Figure 2. 
 
3.2.2 RNA Isolation and DNase Treatment 
1. Collect and pellet cells by centrifugation in a 1.5mL Eppendorf tube. 
2. Follow manufacturer’s protocol (Chomczynski and Sacchi, 1987) using RNA-Bee (see 
Note 11) with the following modifications: 1) For phase separation, shake tube 
vigorously for 30 seconds. 2) For RNA precipitation, let tube sit at room temperature for 
10 minutes before centrifuging at 4°C for 15 minutes. 3) For RNA wash, centrifuge tube 
at 4°C for 10 minutes. 4) For RNA solubilization, dissolve pellet in nuclease-free water 
(see Note 12). 
3. To reduce genomic DNA contamination, treat isolated RNA from the previous step with 
DNaseI using TURBO DNA-free Kit. Follow manufacturer’s protocol exactly, except 
extend the 37°C incubation time to 45 minutes.  
4. Measure the RNA concentration using a NanoDrop spectrophotometer. 
5. Store RNA at -80°C until ready to use for reverse transcription. 
 
3.2.3 Primer Design for Strand-specific Reverse Transcription (RT) and PCR 
1. Design the following primers surrounding the polymorphic sequence as depicted in 
Figure 3. (See Notes 13, 14, 15, and 16)   
i. Tagged RT Primers for the sense transcript (S-RT) and anti-sense transcript 
(ATS-RT): These primers consist of two parts: a 5’ tag and a gene-specific RT 
primer. For the 5’ tag on S-RT, use the following sequence as a template: 5’-
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CAGTCGGGCGTCATCA-3’(Shirk et al., 2013a). For the 5’ tag on ATS-RT, use 
the following sequence from M13R as a template: 5’-
GGAAACAGCTATGACCAT-3’.  Add or remove nucleotides from the ends of 
the primer sequence to optimize the melting temperature and minimize secondary 
structure formation (see Note 17).  For the gene-specific RT primers, use Primer3 
(Koressaar and Remm, 2007; Untergasser et al., 2012) or other similar software to 
design a primer located upstream of the polymorphic sequence on the sense and 
anti-sense transcripts. The melting temperature for these sequences should be 
around or slightly below 55°C (See Note 18).  Check the tag sequence, the gene-
specific RT primer sequence, and the final combined sequence using BLAST or 
UCSC genome browser for mis-priming. 
ii. PCR primer for the tag sequence on S-RT (A): This primer is the same sequence 
as the tag sequence on S-RT. 
iii. PCR primer for the tag sequence on ATS-RT (C): This primer is the same 
sequence as the tag sequence on ATS-RT. 
iv. PCR primer B: This primer is located upstream of the polymorphic sequence on 
the sense transcripts. 
v. PCR primer D: This primer is located upstream of the polymorphic sequence on 
the anti-sense transcripts. 
 
3.2.4 Strand-specific Reverse Transcription (RT)  
1. Follow manufacturer’s protocol for Superscript III. 
2. Set up two RT reactions: one using S-RT as the gene-specific primer and another using 
ATS-RT as the gene-specific primer. For each reaction, include a no RT control that 
contains the same ingredients except for the reverse transcriptase. The no RT controls (S-
noRT and ATS-noRT) will indicate any genomic DNA contamination in the following 
PCR reaction. 
3. Heat the primer/dNTP/DNase-treated RNA mixture in a thermocycler at 65°C for 5 
minutes and cool on ice for at least 1 minute.  
4. After adding the remaining reaction components as instructed, place the tubes in a 
thermocycler and run the following program for reverse transcription: 25°C for 5 minutes, 
55°C for 60 minutes, and 70°C for 15 minutes. 
5. Keep the tubes on ice or store at -20°C until ready to use for the allele-specific PCR. 
 
3.2.5 Allele-specific PCR 
1. Follow manufacturer’s protocol for Advantage 2 Polymerase Mix (or other high-fidelity 
proof-reading DNA polymerase). 
2. Set up two sets of PCR reactions for each S-RT, ATS-RT, S-noRT, ATS-noRT, as well 
as a genomic DNA control (see Note 19). For the first set, use A and B as PCR primers. 
These two primers amplify the sense transcripts specifically. For the second set, use C 
and D as PCR primers which will specifically amplify the anti-sense transcripts. The PCR 
result with different primer combinations is summarized in Figure 4A.  
3. Once the PCR result is verified with strand-specific primers as stated above, you can 
carry out a PCR using primers B and D to obtain an image that is easier to interpret 
visually as shown in Figure 4B (see Note 20). 
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3.3 RNA FISH 
3.3.1 Plate iPSC colonies on coverslips 
1. Plate irradiated mouse embryonic fibroblasts (MEFs) onto 12mm round coverslips 1-2 
days before seeding iPSC colonies on them. 
2. Cut iPSC colonies mechanically and place them on MEF-coated coverslips and let them 
grow in human embryonic stem cell medium for 4-6 days. 
 
3.3.2 Make SNORD115 BAC probes using Nick Translation DNA Labeling System (See 
Note 21) 
1. Dilute Alexa Fluor 594-5-dUTP to 0.3 mM (10 µL of 1 mM Alexa Fluor 594-5-dUTP in 
23.3 uL of nuclease-free water). Keep the unused portion in -20°C and avoid light. 
2. Prepare diluted DNase I freshly (80 µL of 1X DNase dilution buffer and 1 µL of DNase 
I). Gently flick to mix. DO NOT VORTEX!!! 
3. Add the following reagents from the Nick Translation DNA Labeling system accordingly. 
 
SNORD115 BAC 1 µg (Adjust volume to 25 µL with Nuclease-free water) 
Reaction Buffer 5 µL 
dNTP Mix 5 µL 
dTTP 2.5 µL 
0.3 mM Alexa 594-dUTP 2.5 µL 
DNA Polymerase I 5 µL 
Fresh diluted DNase I 5 µL 
Total Volume 50 µL 
 
4. Carefully mix the reagents by flicking and briefly centrifuge. 
5. Incubate the mixture for 2 hours at 15°C. 
6. After incubation, place the reactions on ice. 
7. Terminate the reaction by adding 5 µL of Stop Buffer and heat up for 5 minutes at 65°C. 
Pause point: Labeled BAC probes can be stored at -20°C prior to use. 
 
3.3.3 Make UBE3A riboprobes using MAXIscript T7/T3 Kit (See Note 22) 
1. Clone UBE3A cDNA C7-3 (Kishino and Wagstaff, 1998) into pBluescript SK+. 
2. Linearize the plasmid with Not I (See Note 23). 
3. Add the following reagents from the MAXIscript T7/T3 kit accordingly. 
 
Linearized UBE3A plasmid 1 µg 
10X Transcription Buffer 2 µL 
10 mM ATP 1 µL 
10 mM CTP 1 µL 
10 mM GTP 1 µL 
10 mM UTP 1 µL 
1 mM Alexa 488-UTP 2.5 µL 
T7 or T3 Enzyme (see Note 24) 2 µL 
Nuclease-free water to 20 µL 
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4. Carefully mix the reagents by flicking and briefly centrifuge. 
5. Incubate the mixture for one hour at 37°C. 
6. Add 1 µL of DNase I and incubate at 37°C for 15 minutes to remove any residual DNA.  
Pause point: Labeled riboprobes can be stored at -20°C prior to use. 
7. Take 5 µL of in vitro transcribed riboprobes and hydrolyze it by adding 20 µL carbonate 
buffer and 20 µL of nuclease-free water (See Note 25). 
8. Incubate at 60°C for 30 minutes to obtain the optimal size of riboprobes (See Note 26 
and Figure 5). 
9. Neutralize with 2.5 µL (or 1/20 volume) of 10% acetic acid. 
10. Purify riboprobes by running through a Micro Bio-Spin P-30 Tris column to remove the 
unlabeled Alexa Fluro 488-5-UTP. 
 
3.3.4 Precipitate probes 
1. Add 5 µL of labeled SNORD115 BAC probes to the purified riboprobes (See Note 26). 
2. Add 5 µL of Cot-1 DNA and 5 µL of salmon sperm DNA to the combined probes. 
3. Add 2.5X volume of 100% ice-cold EtOH to the mix. 
4. Mix well and precipitate the probes for 30 minutes at -20°C. 
5. Centrifuge at 12,000 rpm for 30 minutes at 4°C. 
(While waiting for the centrifuge, prepare coverslips and 2X hybridization buffer, See 
3.3.5) 
6. Carefully remove the supernatant and air dry in the dark for at least 15 minutes. 
 
3.3.5 Prepare coverslips and 2X hybridization buffer 
1. Aspirate iPSC medium and wash with PBS once.  
2. Incubate the coverslips with ice-cold CSK buffer for 30 seconds at room temperature. 
3. Incubate the coverslips with ice-cold 1% Triton X-100/CSK buffer for 5-10 minutes at 
room temperature (See Note 27). 
4. Incubate the coverslips with ice-cold CSK buffer for 30 seconds. 
5. Fix the coverslips with 4% paraformaldehyde/PBS for 10 minutes at room temperature.  
Pause point: The coverslips can be stored in 70% EtOH at 4°C until use. 
6.   Dehydrate the coverslips with 85%, 95%, and 100% EtOH for 2 minutes each. 
7. Airdry for 10-15 minutes until everything evaporates. 
8. Make 2X hybridization buffer. 
 
3.3.6 Hybridization 
1. Resuspend the dry pellet in 5 µL 100% formamide and denature the probes at 90-95°C 
for 10 minutes (for 2 coverslips). 
2. Meanwhile, create a humid chamber with 50% formamide /2X SSC. 
3. Add equivalent amount of 2X hybridization buffer to denatured probes, mix well, and 
spin it down. 
4. Wrap a slide with parafilm and apply ~5 µL of denatured probes on the film (avoid 
bubbles). 
5. Put coverslips upside down and make sure iPS colonies are well covered. 
6. Place the slide in the humid chamber and incubate at 37°C overnight. 
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3.3.7 Post-hybridization wash 
1. Take the coverslip and put the side with iPSC colonies up on a new parafilm wrapped 
slide. 
2. Wash with 50% formamide/2X SSC three times at 39°C for 7 minutes. 
3. Wash with 2X SSC three times at 39°C for 7 minutes. 
4. Wash with 1X SSC two times at 39°C for 7 minutes (wash more or less with 1X SSC to 
have best signal/noise ratio). 
5. Airdry the coverslips in the dark until everything evaporates. 
6. Mount it with 3-4 µL Vectashield with DAPI and seal it. 
7. The coverslips are ready for imaging (see Figure 6). 
 
4.  Notes 
1. Alternatively, any commercially available kit can be used to isolate high quality genomic 
DNA. 
2. We often reduce the reaction volume by half when performing this assay using the 
EpiTect Methyl II Restriction Enzyme kit. This results in 15µL of each digested DNA 
which is sufficient to run triplicate qPCR technical replicates using 5µL of DNA per 
qPCR reaction. 
3. It is very important to ensure that each digest tube contains the same amount of DNA. 
4. If using MSREs and MDREs from another source, follow manufacturer guidelines for 
running a standard restriction digest with appropriate volumes of enzyme. 
5. If using PCR primers other than the EpiTect assay, adjust volume of water to 
accommodate volume of PCR primers used. 
6. If using primer sets other than an EpiTect assay, qPCR conditions such as annealing 
temperature will need to be optimized. 
7. According to Bruce et al. (Bruce et al., 2008), in order to calculate percent methylation, 
first subtract the mean Ct value of the Mock digest from the mean Ct value of the MSRE 
reaction to yield value x. Then use the equation: % meth = 100*1/PM where PM = 2x. 
Oakes et al. (Oakes et al., 2006) use a slightly modified equation. Again, subtract the 
mean Ct of the Mock digest from the mean Ct of the MSRE or MDRE reaction to yield 
ΔCt. Then using the ΔCt of MSRE, use the equation: % meth = 100*(e-0.7(ΔCt)) or using 
the ΔCt of MDRE, use the equation: % meth = 100*(1-e-0.7(ΔCt)).  
8. DNA with good quality has a 260/280 ratio of 1.8-2.0 when measured by a NanoDrop 
spectrophotometer. 
9. If there are known heterozygous and homozygous regions for polymorphism, it is a good 
practice to include a positive and a negative control for the T7 E1 assay. 
10. Alternatively, add 0.5ul of 0.5M EDTA if loading dye does not contain EDTA. 
11. Alternatively, use any RNA isolation kit that produces high quality RNA. Note the 
260/280 ratio when measuring RNA concentration with a NanoDrop spectrophotometer. 
High quality RNA extracted by RNA-Bee typically has a ratio of 1.6-1.9.  
12. Do not use DEPC-treated water as it may not be compatible with following experiments. 
13. The RT primers should be within a few hundred nucleotides of the polymorphic region 
for reverse transcription, yet far enough from the polymorphic region to accommodate 
the PCR primers downstream. 
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14. For ease of analysis, the polymorphic region should preferably be located at the center of 
all three primer-pairs so that the resulting PCR products from sense and anti-sense strand 
are similar in size for each allele.  
15. The four PCR primers (A, B, C, and D) should have similar melting temperature so that 
they can be used interchangeably during PCR. 
16. If the polymorphism is a single nucleotide change or the difference in repeat numbers is 
too small to be resolved using gel electrophoresis, sequencing is required to decipher the 
origin of the sense and anti-sense transcripts. In this case, PCR primers B and D can be 
used as sequencing primers and should be located at least 40 nucleotides away from the 
polymorphic region to avoid the initial low quality sequencing reads. 
17. As PCR primers A and C are dependent on the tag sequences in the RT primers, it is 
important to check melting temperatures and secondary structures of the tag sequences. 
Software such as Primer Express® 3.0 is recommended for this purpose. Ideally, these 
sequences should be unique and do NOT align to the host genome to avoid non-specific 
PCR amplification.  
18. The melting temperature of gene-specific RT primer sequences should be similar to the 
optimal working temperature of the reverse transcriptase used. According to 
manufacturer’s protocol, Superscript III works the best at 55°C for gene-specific reverse 
transcription.  
19. When the polymorphic sequence is not centered, the band size between PCR product 
from sense and anti-sense specific PCR amplification will be different. If your 
polymorphism leads to size differences between two alleles, it may be slightly harder to 
interpret visually on a gel. In this case, try carrying out PCR using B and D. This primer 
set is not as specific and may give you false result if the reverse transcription step is not 
specific enough. Other than changing the band size, it should give you similar result in 
terms of number of bands and intensity as using strand-specific primers. 
20. It is advised to do a serial dilution for the genomic DNA control to match the band 
intensity to a similar level as the other samples. 
21. The following steps are adapted from Nick Translation DNA Labeling System protocol 
(catalog #ENZ-42910, Enzo). 
22. The following steps are partially adapted from MAXIscript T7/T3 Kit protocol (catalog 
#AM-1324M, Life Technologies) and Cold Spring Harbor protocol (Ferrandiz and 
Sessions, 2008) 
23. A restriction enzyme that cuts downstream of the template strand of the cDNA plasmid 
should be used to linearize your plasmid.  If the plasmid DNA is not linearized 
completely, heterogeneous and extremely long RNA transcripts will be generated due to 
the processiveness property of RNA polymerases. 
24. Depending on how cDNA is cloned into your vector plasmid, T3 or T7 enzyme would be 
used to produce the right orientation of riboprobes. For example, if cDNA is cloned in the 
T3-T7 direction, T7 enzyme would be used to generate riboprobes that would detect 
sense transcript. 
25. The volume of riboprobe and BAC probe used can be adjusted to obtain optimal FISH 
signal.  
26. Run 1 uL of in vitro transcribed riboprobes (product from step 3.3.3.6) and 5 uL 
hydrolyzed riboprobes (product from step 3.3.3.8) on a 1% agarose gel to obtain optimal 
size for hybridization. The optimal probe size should be less than 250 nucleotides.  
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Larger size of probes cause low penetration of probes. The incubation time can be 
calculated using the following formula: t = (L0-L1) / 0.11 x (L0)(L1), where L0 is the 
original length of transcript and L1 is the desired riboprobe length (Ferrandiz and 
Sessions, 2008). 
27. Increasing the incubation time of 1% Triton X-100/CSK will increase penetration of 
probes into the nuclei. 
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Figure 1. Short tandem repeats in an intron in UBE3A gene shown in USCS genome browser. 
Ideal PCR primers for T7 E1 assay is depicted on top (F: forward primer; R: reverse primer).  
 
 
 
Figure 2. A polymorphism in UBE3A gene verified by T7 E1 assay in a patient iPS cell line. The 
PCR product is around 1.7kb, with the polymorphic sequence located at the center (left lane). 
The non-perfectly matched DNA resulted from the polymorphism is cut by T7 Endonuclease I 
and leads to a 850bp band (right lane). 
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Figure 3. Primer designs for strand-specific reverse transcription and the following PCR 
amplification. The arrow head in each primer points towards the primer’s 3’ direction. 
 
 
 
Figure 4. Allele-specific PCR for sense and anti-sense transcripts across polymorphism. (A) The 
summary of PCR amplification results with different primer combinations. (B) This gel shows 
allele-specific PCR using primer B and D across the polymorphism identified in Fig. 2. The data 
indicates that the allele that expresses UBE3A-ATS transcripts expresses UBE3A sense 
transcripts at a lower level than the other allele. Genomic DNA serves as a positive control for 
PCR amplification (S-RT: reverse transcription using S-RT primer; ATS-RT: reverse 
transcription using ATS-RT primer; gDNA: genomic DNA; S-noRT: no reverse transcriptase 
control for RT using S-RT primer; ATS-noRT: no reverse transcriptase controls for RT using 
ATS-RT primer). 
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Figure 5. Gel electrophoresis of riboprobes. (A) In vitro transcribed and labeled riboprobes. (B) 
Hydrolyzed riboprobes. DNA ladder is used to approximately estimate the size of riboprobes. 
 
 
 
Figure 6. Representative RNA-FISH images. (A) A normal iPSC with UBE3A (green) 
transcribed from both alleles. SNORD115 (red) is not expressed in normal iPSCs. (B) The 
paternal UBE3A is silenced due to aberrant SNORD115 expression in the atypical Prader-Willi 
Syndrome iPSCs. Scale bar: 2µm. 
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2.5 Results 
2.5.1 Generation of iPSCs, Pluripotency Characterization, and Karyotype Analysis 
 AS del 1-0, PWS del 1-1, and PWS del 1-7 were generated following previously 
published retroviral protocols (Chamberlain et al., 2010; Takahashi et al., 2007). PWS 
SD 2-4, 2-8, and 2-9 were derived from patient fibroblasts using the human polycistronic 
STEMCCA lentiviral vector (Martins-Taylor et al., 2014; Somers et al., 2010). For Dup 
15q syndrome, two idic(15) cell lines—idic 1-8 and idic CB-09—were generated with 
retrovirus using patient fibroblasts and with episome using patient umbilical cord blood 
cells, respectively (Germain et al., 2014; Mack et al., 2011). Mat. int dup(15)-02/-12 and 
pat. int dup(15)-04 were generated by using the aforementioned STEMCCA lentiviral 
vector to reprogram patient fibroblasts harboring paternal and maternal interstitial 
duplication of chromosome 15q11-q13.1, respectively (Germain et al., 2014). 
Chromosome 15q11-q13.1 copy number variations and deleted/duplicated locus in all 
cell lines are shown in Figure 2.1. 
 Reprogrammed iPSC colonies with human embryonic stem cell morphology were 
identified and subsequently validated using immunocytochemistry for pluripotency 
markers, NANOG, SSEA4, TRA1-60, and TRA1-81 (Figure 2.2 A-D). Taqman® qRT-
PCR-based gene expression arrays were used to analyze the expression of lineage 
markers for endoderm, ectoderm, and mesoderm in embryoid bodies (EBs) 
spontaneously differentiated for 14-16 days (Figure 2.2 E-F). These data demonstrated 
that all iPSC lines derived here were indeed pluripotent and capable of multi-lineage 
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differentiation. Additionally, karyotyping was carried out by UConn Chromosome Core 
and showed that all iPSCs presented the expected karyotypes (Figure 2.2 G). 
2.5.2 iPSCs Maintain Appropriate DNA Methylation at PWS-IC  
 To confirm that the methylation imprint at PWS-IC was maintained following 
reprogramming, we carried out methylation-specific PCR as well as qRT-PCR based 
DNA methylation analysis. In Figure 2.3 A-C, bisulfite-converted genomic DNA was 
subjected to a multiplex PCR using primers at PWS-IC specific for unmethylated 
paternal allele (bottom band) and methylated maternal allele (top band). As expected, 
only the unmethylated allele was present in AS iPSCs, while only the methylated allele 
was present in PWS iPSCs. In Figure 2.3 D-F, we utilized a more quantitative DNA 
methylation analysis using methylation-sensitive/methylation-dependent restriction 
endonuclease digestion to demonstrate that DNA methylation at PWS-IC was largely 
unchanged between the fibroblasts and their iPSC counterparts. In normal cells with 
one methylated and one unmethylated allele, we observed 50% to 60% methylation (50% 
expected). Less than 1% of methylation was observed in AS cells with one 
unmethylated allele (0% expected), while more than 95% was found in PWS cells with 
one methylated allele (100% expected). In PWS SD cells, PWS-ICs on both alleles were 
present, and 42% to 50% methylation was observed in all but one iPSC line (50% 
expected). The iPSC line with aberrant methylation status (20%) was excluded from 
further study. For pat. int dup(15)-04, which contained one copy of methylated allele and 
two copies of unmethylated allele, the methylation averaged around 25% (33% 
expected). For Mat. int dup(15), which contained two copies of methylated allele and 
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one copy of unmethylated allele, the methylation averaged around  66% (66% 
expected). Finally, for idic 1-8 and idic CB-09, both carrying three copies of methylated 
allele and one copy of unmethylated allele, averages of 76% and 77% methylation were 
observed, respectively (75% expected). 
2.5.3 AS and Dup 15q iPSCs Can Be Differentiated into Functional Neurons 
 AS and Dup 15q syndrome are neurodevelopmental disorder that affect cortical 
functions. We sought to generate functional neurons from AS and Dup15q iPSCs in vitro 
that mimic the cortical population. Using previously published EB protocol (Figure 2.4 
A), we obtained AS and normal neural epithelial cells that expressed PAX6 and formed 
neural rosettes (Figure 2.4 CA, CB, DA). After six weeks of differentiation, neurons 
were positive for MAP2 and TUJ1 (Figure 2.4 BB, CC, DB, DD). S100β-positive 
astrocytes were detected after six weeks of differentiation (Figure 2.4 BC, DB). 
Concomitantly, Synapsin-I-positive cells also appeared around six weeks post-
differentiation, indicating synaptic development (Figure 2.4 CD, DC). After 10 weeks of 
development, extensive neurite outgrowth was observed (Figure 2.4 BA) and some 
neurons exhibited proper localization of voltage-gated channels in the axonal initial 
segments (AIS) shown by PanNav immunostaining (Figure 2.4 CE, CF, DE). 
Importantly, we determined that these neurons are functional by electrophysiology 
(Chamberlain et al., 2010). 
Similarly, using a modified monolayer protocol (Figure 2.4 A), we obtained Dup 
15q neurons that are MAP2-positive, composed of both VGLUT1-positive excitatory 
neurons as well as GAD65-positive inhibitory neurons, after 10 weeks of differentiation 
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(Figure 2.4 Ea, Ec, Ed). These MAP2-positive neurons also showed co-localization of 
the postsynaptic density protein PSD-95 and the presynaptic marker Synapsin-I, 
indicating functional synaptic formation (Figure 2.4 Ee-Ee’’). S100β-positive astrocytes 
were detected in the monolayer neural culture (Figure 2.4 Eb). Importantly, these 
neurons are electrophysiologically functional and comparable to neurons generated 
using the EB protocol (Germain et al., 2014). 
2.5.4 UBE3A Is Imprinted In AS iPSC-Derived Neurons 
 In order to model AS and Dup 15q syndrome using iPSCs and iPSC-derived 
neurons, it was necessary to ensure that UBE3A was imprinted in neurons as observed 
in vivo. Using qRT-PCR, we compared UBE3A expression of AS cells, which contained 
a single paternal copy of UBE3A, to that of normal cells, which contained both copies of 
UBE3A. We showed that UBE3A expression level was lower in AS iPSCs when 
compared to normal iPSCs, and was further decreased in AS iPSC-derived neurons, 
demonstrating the epigenetic silencing of paternal UBE3A upon neural differentiation 
(Figure 2.5 A). UBE3A expression levels were not significantly different between 
normal iPSCs and normal iPSC-derived neurons, which were consistent with the 
UBE3A protein levels assayed by Western blotting (Figure 2.5 B). Lower levels of 
UBE3A expression in AS iPSCs and AS iPSC-derived neurons were also reflected in 
the protein level. Using Western blotting, we showed that UBE3A protein was drastically 
reduced in AS iPSCs compared to normal iPSCs, and that it was almost undetectable in 
AS iPSC-derived neurons (Figure 2.5 B). 
! 44!
Although the mechanism is yet to be elucidated, neuron-specific paternal UBE3A 
repression is thought to be regulated by active transcription of UBE3A-ATS, which is 
part of the SNURF/SNRPN lncRNA. To determine whether transcripts resulted from 
SNURF/SNRPN lncRNA demonstrate expected tissue-specificity, we analyzed spliced 
exons in the SNORD116 cluster, the SNORD115 cluster, as well as UBE3A-ATS using 
RT-PCR (Figure 2.5 C). We showed that SNORD116 was expressed in iPSCs, neural 
precursors, and neurons. SNORD115 was not expressed in iPSCs, but in both neural 
precursors and neurons. As expected, UBE3A-ATS expression was restricted to iPSC-
derived neurons. Due to the fact that the AS iPSCs and iPSC-derived neurons harbor a 
large deletion on maternal chromosome 15q11-q13.1, we were able to study gene 
expression in an allele-specific fashion. For other cells, such as normal, PWS SD, and 
Dup 15q, that contain more than one copy of chromosome 15q11-q13.1, it is essential 
to study genomic imprinting using tools that can distinguish one allele from another. Two 
of the techniques we utilized for this purpose are allele-specific PCR and RNA FISH, as 
described previously in Section 2.4 (Chamberlain et al., 2016). 
2.5 Discussion 
 We derived patient-specific iPSCs carrying a variety of copy number variations at 
chromosome 15q11-q13.1 that led to AS, PWS, and Dup 15q syndrome. To address 
whether iPSC models are appropriate for studying these imprinting disorders, we 
demonstrated that DNA methylation at PWS-IC is resistant to the global erasure during 
the reprogramming process. Our observation supports the notion that epigenetic marks 
at this locus are established prior to or during early stage of preimplantation (El-Maarri 
! 45!
et al., 2001). Although the AS and Dup 15q iPSCs we derived carry mutations that lead 
to neurodevelopmental disorders, we were able to differentiate all cell lines into mature 
and functional neurons. The developmental timing of neural differentiation for these 
diseased iPSCs closely followed that for normal iPSCs. This is in agreement with the 
fact that, other than micro/macrocephaly, there is no gross brain structural difference 
between AS and Dup 15q patients compared to normal individuals (Battaglia, 2008; 
Williams et al., 2010a). 
 Using AS iPSCs and iPSC-derived neurons, we demonstrated that UBE3A on the 
paternal allele is properly silenced in a neuron-specific manner. We did not observe a 
decrease in UBE3A RNA and protein level in normal iPSC-derived neurons compared to 
normal iPSCs. This could be attributed to upregulated maternal UBE3A expression in 
mature neurons (Dindot et al., 2008). Moreover, we found that different parts of 
SNURF/SNRPN lncRNA exhibit different tissue-specificity—the more distal, the more 
neuron-specific. The most distal part of SNURF/SNRPN lncRNA, UBE3A-ATS, plays an 
important role in paternal UBE3A silencing in neurons.  
Techniques that distinguish allele-specific gene expression are instrumental in 
understanding gene regulation at imprinted locus. For example, we found that PWS SD 
iPSCs carrying an atypical microdeletion aberrantly express SNORD115 and UBE3A-
ATS (Martins-Taylor et al., 2014). This observation suggests the presence of a 
boundary element in non-neuronal cells that suppresses downstream SNURF/SNRPN 
lncRNA expression. We speculate polyadenylation signals in IPW and several CTCF 
binding sites downstream of IPW may be responsible for this boundary function. We 
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also concluded that the expression of UBE3A-ATS alone is sufficient to silence UBE3A 
in cis and that additional neural factors are not necessary (Martins-Taylor et al., 2014).  
 In conclusion, we demonstrated that iPSCs and iPSC-derived neurons are great 
tools for understanding gene regulation at human chromosome 15q11-q13.1.  This in 
vitro model system is not only useful for understanding disease mechanism for AS, 
PWS, and Dup 15q syndrome, but also can be used for drug screening to develop 
therapies (Germain et al., 2014; King et al., 2013; Martins-Taylor et al., 2014).  
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Figure 2.1. Map of the chromosome 15q11-q13.1 region (adapted from Germain et 
al., 2014). Genes are displayed as rectangles (grey: biallelically expressed; red: 
maternally expressed; blue: paternally expressed; black: silenced). Small nucleolar RNA 
clusters are shown as vertical lines. Stripes marking ATP10A indicates variable 
imprinting status depending on individuals. The dotted line represents UBE3A-ATS long 
non-coding RNA transcript. Red and blue shaded areas are the Angelman syndrome 
and Prader-Willi syndrome imprinting centers (AS-IC and PWS-IC), respectively. 
Differentially methylated regions are denoted with ovals (white: unmethylated CpG 
islands; black: methylated CpG islands). Right below the map is a list of AS, PWS, and 
Dup 15q patient-derived iPSC lines. Regions deleted (dashed rectangles) or duplicated 
(continuous rectangles) as well as the respective maternal (M) or paternal (P) 
chromosome 15 allele copy numbers are indicated [PAT: paternal allele; MAT: maternal 
allele; BP: breakpoint; Cen: centromere; Tel: telomere; *mutated].   
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Figure 2.2. AS, PWS, and Dup 15q iPSCs are pluripotent and have expected 
karyotypes (Chamberlain et al., 2010; Germain et al., 2014; Martins-Taylor et al., 2014). 
A-D) AS, PWS, and Dup 15q iPSCs show hESC-like morphology and express 
pluripotency markers, NANOG, SSEA4, TRA1-60, and TRA1-81. E-F) AS, PWS, and 
Dup 15q iPSCs are capable of multi-lineage differentiation. Spontaneously differentiated 
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14- to16-day AS, PWS, and Dup 15q EBs express early lineage markers for all three 
embryonic germ layers by qRT-PCR. G) Karyotype analysis show expected 
chromosome counts in representative AS, PWS, and Dup 15q iPSC lines. Red box 
indicates the expected supernumerary isodicentric chromosome 15. 
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Figure 2.3. DNA Methylation imprint at the PWS-IC is maintained during 
reprogramming (Chamberlain et al., 2010; Germain et al., 2014; Martins-Taylor et al., 
2014). A-C) Methylation-specific PCR analysis of genomic DNA from normal, AS, PWS 
fibroblasts (A) and iPSCs (B-C). Primers specific for the methylated allele amplify a 174 
bp band, while those for the unmethylated allele a 100 bp band [Mat: maternal allele; 
Pat: paternal allele; Neg.: negative control]. D-F) qRT-PCR-based DNA methylation 
analysis using genomic DNA shows expected methylation status at PWS-IC predicted 
by allele copy number and parental origin. The averages of percent methylation plus or 
minus the standard deviation from three replicates are shown. 
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Figure 2.4. Characterization of neurons derived from AS and Dup 15q iPSCs 
(Chamberlain et al., 2010; Germain et al., 2014). A) Schematics of neural differentiation 
process using EB and monolayer protocols. BA) Phase-contrast of 10-week-old AS 
iPSC-derived neurons. BB) AS iPSC-derived neurons stain positively for βIII-TIBULIN 
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(TUJ1, in green) BC) S100β-positive astrocytes are present in AS iPSC-derived neuron 
cultures after 6 weeks of differentiation. CA) AS iPSC-derived neural epithelial cells are 
PAX6-positive (green). CB) Neural rosette formation in AS iPSC-derived neural 
epithelial culture. CC-CD) 6-week-old AS iPSC-derived neurons express MAP2 (CC, in 
red) and βIII-TIBULIN (CD, in green), and show SynapsinI-positive puncta (CD, in red, 
arrows). CE-CF) Immunocytochemistry for PanNav (green) shows lack of voltage-gated 
sodium channel localization in the AIS in most neurons (CE), but proper localization in 
some neurons (CF, arrow). DA) normal iPSC-derived neural epithelial cells are PAX6-
positive (green). DB-DC) 6-week-old normal iPSC-derived neuron cultures contain 
S100β-positive astrocytes (DB, in red) and βIII-TIBULIN-positive neurons (green), which 
show SynapsinI-positive puncta (DC, in red). DD-DE) 10-week-old normal iPSC-derived 
neurons express MAP2 (red) and show lack of voltage-gated sodium channel 
localization in the AIS in most but not all (arrows) neurons by PanNav 
immunocytochemistry (green). Ea) 10-week-old Dup 15q iPSC-derived neurons express 
MAP2 (red). Eb-Ed) 10-week-old Dup 15q iPSC-derived neuron cultures contain S100β-
positive astrocytes (Eb, in red), VGLUT1-positive excitatory neurons (Ec, in green), and 
GAD65-positive inhibitory neurons (Ed, in red). Ee-Ee’) MAP2-positive neurons (red) 
show PSD-95-positive (Ee, in green) and SynapsinI-positive (Ee’, in blue) puncta. Ee’’) 
Merged image shows formation of functional synapses with of PSD-95 and SynapsinI 
co-localization. 
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Figure 2.5. AS iPSC-derived neurons show paternal UBE3A silencing 
(Chamberlain et al., 2010). A) qRT-PCR analysis showing relative UBE3A expression 
levels in normal iPSC-derived neurons, AS iPSCs, and AS iPSC-derived neurons when 
compared to UBE3A expression level in normal iPSCs. B) Western blot analysis 
showing UBE3A protein level in normal and AS iPSCs (I) and 10-week-old iPSC-derived 
neurons (N). C) RT-PCR analysis showing SNORD116, SNORD115, and UBE3A-ATS 
expression in iPSCs (I), 3-week-old iPSC-derived neural precursors (P), and 10-week-
old iPSC-derived neurons (N). 
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Chapter 3 
Generation of a UBE3A Reporter Cell Line by Genome Editing 
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3.1 Background and Significance 
Observations made in murine models indicate that Ube3a protein expression and 
localization is dynamic during neurodevelopment (Dindot et al., 2008; Judson et al., 
2014). Specifically, Judson et al. utilized knockin mice expressing yellow fluorescent 
protein (YFP) fused to the C-terminus of Ube3a to demonstrate the spatiotemporal 
characteristic of Ube3a expression from paternal or maternal allele in developing 
postnatal brain. In addition to showing maternal-specific Ube3a expression in mature 
neurons, they identified postnatal neural stem cells and oligodenrocytes to be the two 
cell populations expressing Ube3a biallelically. Interestingly, some characteristic 
phenotype of AS patients, such as cognitive impairment and white matter abnormalities, 
may be related to aberrant neural stem cells and oligodendrocyetes, respectively 
(Judson et al., 2014). Further study is required to determine whether loss of maternal 
Ube3a expression/function in these two cell types can lead to haploinsufficiency and, 
therefore, contribute to AS manifestation. 
In addition, Judson et al. reported a shift in subcellular localization of Ube3a, from 
cytoplasmic to nuclear, during the first postnatal month. Ube3a expression at embryonic 
stage rescues phenotypes across multiple domains in AS mice, including behavioral 
phenotypes that cannot be rescued at postnatal stages (Silva-Santos et al., 2015). 
Taken together, this suggests that cytoplasmic Ube3a may play a major role in early 
brain development. Incidentally, impaired dendrite polarity caused by Ube3a knockdown 
in mice could only be rescued by expressing full-length cytoplasmic Ube3a isoform 2 
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(Miao et al., 2013). These observations suggest that cytoplasmic Ube3a may be the 
most relevant isoform for developing therapies for AS. 
Studies mentioned above are informative in determining affected cell populations, 
treatment windows, and UBE3a isoform selection for treating AS. However, mouse brain 
is fundamentally different from human brain and lacks gyrification, which is important for 
higher cognitive functions. In order to translate these findings into treatments for AS 
patients, it is necessary to understand whether UBE3A protein expression and 
subcellular localization are similarly regulated in human neural tissues. It is also 
important to determine the timing of paternal UBE3A silencing in human, so that 
neurodevelopmental stages critical for AS between human and mice can be better 
correlated. To address these issues, we attempted to create an UBE3A-GFP fusion 
protein reporter using AS iPSCs, using a design similar to the YFP knockin mice 
previously mentioned. However, we were unable to detect abundant UBE3A-GFP fusion 
proteins in these cells, most likely caused by low expression or instability at the protein 
level. Nevertheless, a successful UBE3A-GFP reporter AS iPSC line would be 
informative on spatiotemporal regulation of UBE3A expression during human 
neurodevelopment as well as a useful tool for high throughput drug screening for AS 
treatments. 
3.2 Rationale 
One difficulty that scientists faced when determining allele-specific Ube3a protein 
expression and subcellular localization using immunofluorescent staining was poor 
assay sensitivity. Judson et al. was able to improve immunofluorescent staining protocol 
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to detect low level of endogenous Ube3a expression from paternal allele in mice. 
However, currently available UBE3A antibody does not work well in human neurons. 
Since Ube3a-YFP fusion protein was stable in mice, and its subcellular localization 
agreed with native Ube3a localization observed using immunofluorescent staining 
(Judson et al., 2014), we utilized a recently developed gene-editing technology, 
CRISPR/Cas9, to create a cell line expressing enhanced green fluorescent protein (GFP) 
fused to the C-terminus of Ube3a. We chose to use AS iPSCs to construct this reporter 
cell line, because of the ease in targeting the single paternal copy of UBE3A gene. The 
detailed targeting vector and CRISPR/Cas9 construct design is described below (Figure 
3.1A).  
3.3 Materials and Methods 
iPSC line and Maintenance 
AS del 1-0 iPSCs were used in this study and maintained as described before 
(Chamberlain et al., 2010). Briefly, iPSCs were grown on irradiated mouse 
embryonic fibroblasts (iMEFs) and fed daily with conventional hESC medium 
consisting of DMEM-F12 supplemented with knock-out serum replacer, 
nonessential amino acids, L-glutamine, β-mercaptoethanol, and basic FGF. 
iPSCs were cultured in a humid incubator at 37 °C with 5% CO2 and passaged 
approximately once a week manually. 
sgRNA and UBE3A-GFP Construct Design for Gene Editing 
CRISPR/Cas9 and UBE3A-GFP vectors were designed and constructed by 
Christopher Stoddard of the hESC/iPSC Targeting Core at the University of 
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Connecticut Health Center. AGGCCATCACGTATGCCAA is the small guide RNA 
sequence targeting the last exon of UBE3A, and it was cloned into a human 
codon-optimized SpCas9 and chimeric guide RNA expression plasmid, pX330 
(Addgene plasmid #42230) (Cong et al., 2013). The UBE3A-GFP targeting vector 
contains a loxP-flanked neomycin resistance gene for drug selection and a 
diphtheria toxin A gene for negative selection. The targeting vector also lacks the 
guide sequence to prevent CRISPR/Cas9-mediated cutting. The detailed design 
for the targeting construct is depicted in Figure 3.1. 
Nucleofection and Drug Selection 
10μM ROCK inhibitor, Y-27632, was added to iPSC colonies overnight prior to 
nucleofection. iPSCs were singlized with Accutase and counted using a 
hemocytometer. 1~2 million cells were used for each experiment. Cells were 
pelleted by centrifugation at 1400rpm and preplated into one well of a 6-well 
tissue culture plate for 1~2 hours to remove feeder cells. Nucleofection was 
carried out following the manufacturer’s protocol for Human Stem Cell 
Nucleofector Kit 1 and 2 (Lonza). 3μg of sgRNA/Cas9 vector and 3μg of UBE3A-
GFP targeting construct were used for each nucleofection. Nucleofector 
programs A-023 and B-016 were used in combination with Human Stem Cell 
Nucleofector Kit 1 and 2, respectively. Cells were then plated into one well of a 6-
well tissue culture plate coated with DR4-iMEF feeders in the presence of 10μM 
ROCK inhibitor overnight. The morning after nucleofection, old medium was 
removed and fresh hESC medium with 10μM ROCK inhibitor was added to the 
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cells. ROCK inhibitor was removed from the culture medium the following day. 96 
hours post-nucleofection, cells were drug selected using 25μg/mL G418 for one 
passage. Single colonies were manually split into a 24-well tissue culture plate 
coated with DR4-iMEF feeders and numbered. Half of each iPSC colony was 
saved for genotyping. One-day post splitting, G418 concentration was increased 
to 50μg/mL to eliminate false positive clones. Targeted clones were drug 
selected with G418 at 50μg/mL for an additional passage and then cultured in 
regular hESC medium on normal iMEFs. Neomycin resistance gene containing a 
polyadenylation signal sequence was removed from the last intron of UBE3A by 
Cre-Lox recombination. 5 μg of Cre-IRES-PuroR vector (Addgene plasmid 
#30205) was nucleofected in to about 1 million cells as described above to 
transiently express Cre (Somers et al., 2010). Nucleofected cells were seeded 
into one 6-well tissue culture plate coated with DR4-iMEF feeders. 24 hours post-
nucleofection, cells were drug selected using 1μg/mL puromycin for 48 hours. 
Individual colonies were manually split onto regular iMEFs and genotyped. 
Genotyping Targeted Clones 
Genomic DNA from half of each iPSC colony was prepared using hot sodium 
hydroxide and tris (HotSHOT) (Truett et al., 2000) (protocol available on 
http://gttf.uchc.edu/protocols/hotshot.html). Briefly, cells were pelleted in a 
microcentrifuge tube by spinning at top speed in a tabletop centrifuge for 30 
seconds. Excess culture medium was carefully removed by aspiration without 
perturbing the pellet. Pelleted cells were incubated in 30μL Alkaline Lysis 
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Reagent (25mM NaOH; 0.2mM EDTA) at 95°C for at least one hour and chilled 
on ice. Then, 30μL of Neutralization Reagent (40mM Tris-HCl) was added to 
each tube and mixed well. For each sample, 1~3μL of HotSHOT DNA per PCR 
reaction was used for genotyping. Primers for HotSHOT PCR were designed to 
produce products smaller than 500bp. Presences of GFP and neomycin 
resistance gene (Neo) were used in the initial screening to rule out untargeted 
cells. GFP+/Neo+ colonies were expanded and high quality genomic DNA was 
prepared using phenol/chloroform extraction. Proper integration of UBE3A-GFP 
targeting vector was assayed by sequential PCR amplification for 5’ and 3’ 
homologous recombination. Presence of wild type UBE3A was assayed using 
sequential PCR amplification. DNA sequencing was done at the fusion site of 
UBE3A and GFP. The resulting clones were expanded and subjected to Cre-Lox 
recombination. HotSHOT PCR with various primer sets were used to genotype 
wildtype, targeted Neo+, and targeted Neo- clones. For primers used in this 
project, see Appendix A. 
RNA Isolation and Reverse Transcription 
RNA samples were isolated using RNA-Bee (Tel-Test Inc.) and converted into 
cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
according to the manufacturer’s instructions. 
Immunocytochemistry 
Immunocytochemistry was carried out as previously described (Chamberlain et 
al., 2010). Mouse anti-GFP (1:150, MAB3580, Chemicon) was used as primary 
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antibody and AlexaFluor 488 conjugated goat anti-mouse (1:300, Life 
Technologies) was used as secondary antibody. Nuclei were counterstained with 
DAPI and coverslips were mounted on slides with Vectashield (Vector 
Laboratories). Slides were imaged using a Zeiss Axiovision microscope. 
Western Blotting 
Cells were lysed on ice using RIPA buffer (150mM NaCl; 50mM Tris, pH 8.0; 1% 
TritonX-100; 0.5% Sodium Deoxycholate; 0.1% SDS) supplemented with 
proteinase inhibitor II. Protein concentrations were measured using Peirce BCA 
Protein Assay Kit (Thermo Scientific). Total cell lysates were resolved on 10% 
handcast SDS-PAGE gels and transferred to nitrocellulose membranes using 
wet/tank blotting system (Bio-Rad). The membranes were blocked in 5% nonfat 
dry milk in TBST (0.5% Tween-20 in TBS containing 20mM Tris and 500mM 
NaCl), followed by overnight incubation with primary antibody, rabbit anti-UBE3A 
(1:1000, A300-352A, Bethyl). After washing with TBST three times, membranes 
were blotted with goat anti-rabbit secondary antibody conjugated with 
horseradish peroxidase for one hour. Membranes were washed and then 
developed in Immobilon Western Chemiluminescent HRP Substrate (Millipore), 
detected using X-ray films (Kodak). 
3.4 Results 
GFP was inserted into the last exon of UBE3A on the paternal allele in AS iPSCs 
using CRISPR/Cas9-mediated gene editing (Figure 3.1A). Primers for genotyping are 
depicted in Figure 3.1B and all primers used in this chapter are listed in Appendix A. 
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For initial screening, GFP+/Neo+ clones were identified using HotSHOT PCR (Figure 
3.2A). Purity of UBE3A-GFP clones was assayed by endogenous UBE3A-specific 
sequential PCR on genomic DNA (Figure 3.2B). This data suggests that the clones 
were targeted and no wild type UBE3A existed in their genome.  
Successful targeting events were confirmed by sequential PCR for 5’ and 3’ 
homologous recombination (Figure 3.2C). Clones with both 5’ and 3’ homologous 
recombination were selected and subjected to Cre-Lox recombination to remove 
neomycin resistance gene (Figure 3.3). Based on this PCR result, we had technical 
difficulties in acquiring pure Neo- UBE3A-GFP clones. However, we thought that the 
presence of neomycin resistance gene was unlikely to have adverse effect on UBE3A-
GFP expression, as it resides in an intron. In-frame GFP insertion in these clones was 
confirmed by DNA-sequencing (Figure 3.4A). RNA expression of wild type UBE3A and 
UBE3A-GFP transcripts was assessed by conventional PCR (Figure 3.4B). 
Unexpectedly, we saw a low level of wild type UBE3A expression in the UBE3A-GFP 
clones that do not have wild type UBE3A based on genotyping. This artifact is likely 
caused by inappropriate primer design that non-specifically amplifies UBE3A-GFP 
transcripts at low efficiency.  
UBE3A-GFP fusion protein expression was determined by immunocytochemistry 
(Figure 3.5A) and western blotting (Figure 3.5B). Fluorescence from UBE3A-GFP 
fusion proteins was not visible without antibody amplification under fluorescence 
microscope. This is expected because antibody amplification was also required to 
detect protein expression in the Ube3a-YFP knockin mice (Dindot et al., 2008; Judson 
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et al., 2014). However, to our surprise, we were unable to detect UBE3A-GFP fusion 
proteins by western blot using antibody against UBE3A, which differed from previously 
published data (Dindot et al., 2008). 
3.5 Discussion 
CRISPR/Cas9-mediated UBE3A-GFP gene targeting was successful. No wild 
type UBE3A was detected by genotyping. The last two base pairs at the 3’ end of 
reverse primer designed to specifically detect wild type UBE3A RNA transcript overlaps 
with UBE3A-GFP transcript, and therefore may bind and amplify UBE3A-GFP at a low 
efficiency. This indicates that the low level wild type UBE3A expression in Figure 3.4B 
may be an artifact.  
The reporter cell lines created here are not as useful for studying spatiotemporal 
regulation of UBE3A expression and drug screening than we expected initially because 
of the following two reasons. First, GFP florescence level in these cells was 
undetectable without immunofluorescent staining and only visible at high magnification 
(63x with oil) even with GFP antibody amplification. To study the timing of paternal 
UBE3A silencing, immunofluorescent staining would have to be carried out at multiple 
time points during neural differentiation, and paternal UBE3A expression in individual 
cells can not be followed by live cell imaging. Having to amplify the fluorescent signal 
also increases the difficulty to use these cell lines for high-throughput drug screening. 
Second, we could not detect UBE3A-GFP fusion protein using an antibody against 
native UBE3A protein. This antibody recognizes the middle section of UBE3A protein, 
400~450aa, which should be identical between wild type UBE3A and UBE3A-GFP 
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fusion proteins. As proteins were denatured for western blotting, it is unlikely that 
structural changes interfere with protein detection. This suggests that the UBE3A-GFP 
fusion protein was either expressed at a very low level or unstable and degraded soon 
after translation.  
There are several prospects that can lead to low UBE3A-GFP fusion protein 
expression or stability. At RNA level, one possibility is that we were unable to efficiently 
remove neomycin resistance gene through Cre-Lox recombination. The neomycin 
resistance gene contained a polyadenylation signal sequence, and, although residing in 
an intron and should be removed by splicing, its presence may still affect UBE3A-GFP 
RNA transcription or stability. In Ube3a-YFP mice, loxP-flanked neomycin resistance 
gene was positioned after YFP stop codon and before the native 3’ UTR of UBE3A, 
which may reduce its interference on RNA transcription or stability. In Figure 3.4B we 
assessed UBE3A-GFP RNA level by conventional PCR. Despite the fact that this 
method was not quantitative, we showed a strong UBE3A-GFP expression. This 
suggests that low expression and instability of UBE3A-GFP may occur at the protein 
level.  
In our targeting construct, GFP was inserted into a cut site located within the last 
exon of UBE3A, separating the final six amino acids from the rest of UBE3A protein 
sequence. Additionally, five amino acids were deleted at the cut site to protect targeting 
construct from CRISPR/Cas9-mediated cutting. As a result, the last 11 amino acids of 
UBE3A were disrupted by the GFP insertion in our targeting construct. The UBE3A C-
terminus encodes for a HECT domain, which is important for UBE3A ligase activity. 
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Many non-truncating mutations right before these 11 amino acids are linked to AS, 
indicating that any changes at this locus may affect UBE3A function or integrity. 
Furthermore, this protein sequence is 100% conserved in all species available on UCSC 
genome browser, from human to lamprey. We speculate that disruption at the UBE3A 
C-terminus was the cause for low UBE3A-GFP expression and/or instability in the 
reporter cell lines we derived. In Ube3a-YFP mice, the YFP was fused in-frame to a full 
length Ube3a protein without any sequence perturbation, other than removal of the 
Ube3a stop codon. 
To create a better UBE3A-GFP reporter cell line, two changes should be made in 
the construct designs. First, the small guide RNA should be designed to target the 3’-
UTR of UBE3A for CRISPR/Cas9-mediated cutting. The resulting 3’-UTR will miss 15 
nucleotides to protect targeting construct from CRISPR/Cas9-mediated cutting, but no 
sequence alteration will be introduced to UBE3A-GFP protein. Second, the targeting 
construct should be designed according to that used for Ube3a-YFP mice, with a full-
length UBE3A fused to GFP and neomycin resistance gene between GFP and the 3’ 
UTR (Dindot et al., 2008). This experimental design should lead to reporter cell lines 
that express stable UBE3A-GFP fusion protein. 
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Figure 3.1. UBE3A-GFP construct and genotyping primer design. A) UBE3A-GFP 
targeting vector showing CRISPR/Cas9-mediated homologous recombination. UCSC 
genome browser on top shows edited UBE3A locus. B) Genotyping primers used to 
determine 5’/3’ homologous and Cre-Lox recombination. Dashed lines indicate 
endogenous genomic sequences outside of homologous arms. 
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Figure 3.2. UBE3A-GFP genotyping result using PCR and gel electrophoresis. A) 
HotSHOT PCR screening for GFP+/Neo+ clones. One UBE3A-GFP clone showed only 
Neo cassette integration (left) and another showed correct targeting with both Neo and 
GFP integration (second to the left).  B) Sequential PCR on genomic DNA using wild 
type UBE3A specific primers showed that wild type UBE3A was not present in UBE3A-
GFP clones. C) PCR shows proper homologous recombination on 5’- and 3’- arms (HR) 
[Ctrl: control; 1°: primary; 2°: secondary; No Temp.: no template control; 1kb+ M.: 1kb+ 
DNA marker]. 
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Figure 3.3. Genotyping PCR result for Cre-Lox recombination. Example gel images 
for Cre-Lox recombination to remove neomycin resistance gene from UBE3A intron. 
PCR products from the original UBE3A-GFP targeted clone were ran on the left of 1kb+ 
DNA ladder. PCR products from 12 daughter clones that were nucleofected and drug 
selected to transiently express Cre were ran on the right-hand side of the ladder. Primer 
sets indicated in the brackets correspond to Figure 3.1B and Appendix A. 
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Figure 3.4. UBE3A-GFP DNA sequencing and RNA expression. A) Genomic DNAs 
from targeted clones were subjected to PCR amplification using primers across UBE3A 
and GFP fusion site and sequenced using a nested sequencing primer. GFP sequences 
are shaded in blue. B) RNA isolated from UBE3A-GFP targeted clones were reverse 
transcribed and amplified by PCR using wild type UBE3A or UBE3A-GFP primers. Wild 
type UBE3A expression in UBE3A-GFP clones is likely an artifact caused by poor 
primer specificity to wild type UBE3A. 
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Figure 3.5. UBE3A-GFP protein expression. A) Immunocytochemistry using antibody 
against GFP (green) to amplify UBE3A-GFP fluorescent signals. B) Western blot using 
antibody against UBE3A to detect UBE3A-GFP (not observed) in targeted clones and 
wild type UBE3A (*) in H9 hESC and AS del 1-0 iPSC controls.  
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Chapter 4 
RBFOX1 and RBFOX2 are dispensable in iPSCs and iPSC-derived neurons and 
do not contribute to neural-specific paternal UBE3A silencing 
 
 
 
 
 
 
 
 
 
 
This chapter is a manuscript under review.  
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4.1 Abstract  
Angelman Syndrome (AS) is a rare neurodevelopmental disorder caused by loss 
of function of the maternally inherited copy of UBE3A, an imprinted gene expressed 
biallelically in most tissues, but expressed exclusively from the maternal allele in 
neurons.  Active transcription of the neuron-specific long non-coding RNA (lncRNA), 
UBE3A-ATS, has been shown to silence paternal UBE3A.  We hypothesized that 
alternative splicing factors, RBFOX2 and RBFOX1, might mediate splicing changes and 
result in the transcription of UBE3A-ATS in neurons. We found that RBFOX2 and 
RBFOX1 both bind to UBE3A-ATS transcript in neurons, but are not required for gene 
expression and/or neuron-specific processing in the SNURF/SNRPN-UBE3A region. 
However, we found that depletion of RBFOX2 causes a proliferation phenotype in 
immature neural cultures, suggesting that RBFOX2 is involved in division versus 
differentiation decisions in iPSC-derived neural progenitors. Absence of RBFOX2 also 
altered the expression of some genes that are important for glutamatergic neocortical 
development and Wnt-Frizzled signalling in mature neuronal cultures. Our data show 
that while RBFOX1 and RBFOX2 do not mediate neuron-specific processing of UBE3A-
ATS, these proteins play important roles in developing neurons and are not completely 
functionally redundant.  
4.2 Introduction 
Angelman syndrome (AS), a neurodevelopmental disorder affecting 
approximately 1/15,000-1/30,000 live births (Chamberlain and Lalande, 2010b), is 
characterized by microcephaly, seizures, ataxia, lack of speech, happy demeanor, and 
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severe cognitive disability (Lossie et al., 2001). AS is caused by the loss of function from 
the maternal copy of the UBIQUITIN PROTEIN LIGASE E3A (UBE3A) gene (Kishino et 
al., 1997). UBE3A is imprinted, and expressed preferentially from the maternal allele in 
neurons, but is expressed from both parental alleles in other tissues. This tissue-specific 
imprinting—or silencing of paternal UBE3A—occurs due to the neuron-specific 
expression of an antisense transcript (UBE3A-ATS) from the paternal allele 
(Chamberlain et al., 2010). UBE3A-ATS is one of several lncRNAs that are processed 
from the SNURF/SNRPN gene. In addition to the protein-coding SNURF and SNRPN 
transcripts, this gene also produces several members of the SNORD116 and 
SNORD115 snoRNA clusters, as well as lncRNAs of unknown function, such as 
IMPRINTED IN PRADER-WILLI (IPW) and UBE3A-ATS (Runte et al., 2001). The 
neuron-specific regulation of UBE3A-ATS is poorly understood, but likely differs 
between mouse and human. In mouse, the entire lncRNA portions of the Snurf/Snrpn 
transcript are neuron-specific (Landers et al., 2004).  In human, the lncRNAs between 
SNURF/SNRPN protein-coding portion and the IPW lncRNA are expressed broadly in 
many tissue types, but the lncRNA downstream of IPW, including the SNORD115 
cluster and UBE3A-ATS are neuron-specific (Chamberlain et al., 2010). It is important to 
understand the regulation of the neuron-specific portion of SNURF/SNRPN lncRNA, 
since it, in turn, controls UBE3A imprinted expression (Huang et al., 2012; Meng et al., 
2015). 
A previous crosslinking-immunoprecipitation-sequencing (CLIP-Seq) study in 
human embryonic stem cells (hESCs) showed that the SNURF/SNRPN lncRNA is 
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highly bound by an alternative splicing factor, RBFOX2 (data available at 
http://genome.ucsc.edu) (Yeo et al., 2009). RBFOX2, also known as RBM9, belongs to 
the RBFOX1 family of RNA-binding proteins (Nakahata and Kawamoto, 2005). RBFOX2 
and its paralogs, RBFOX1 (A2BP1) and RBFOX3 (HRNBP3), are known to be key 
regulators of alternative splicing in neurons and regulate exon exclusion/inclusion as 
well as intron retention (Kim et al., 2010; Nakahata and Kawamoto, 2005; Underwood et 
al., 2005). All three RBFOX proteins are known to bind to the hexanucleotide sequence 
UGCAUG, a common cis-regulatory element in pre-mRNAs. Mouse studies suggest that 
RBFOX1 is highly expressed in heart, brain, and muscles while RBFOX2 is expressed 
in a broader range of tissues, including the aforementioned as well as ovary, kidney, 
lung epithelium, and embryo (Underwood et al., 2005). In comparison, RBFOX3 is not 
as well characterized and is identified to encode a neuron-specific nuclear protein that is 
recognized by NeuN antibody (Kim et al., 2009). Recent studies indicate that RBFOX 
proteins may be involved in alternative polyadenylation regulation and affect functions 
related to 3’ untranslated regions (UTRs), such as mRNA stability, localization, and 
translation (Shi et al., 2009; Wang et al., 2008). Interestingly, RBFOX1 
haploinsufficiency is linked to autism, intellectual disability, and epilepsy (Bill et al., 
2013).  
High-throughput sequencing studies of 3’ polyadeylated ends (polyA-Seq) in 
human tissues revealed two polyadenylation sites at the 3’ end of IPW near the end of 
the SNURF/SNRPN lncRNA transcript in non-neuronal cells (Derti et al., 2012).  We 
hypothesized that the neuron-specific expression of RBFOX1 regulates an alternative 
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splicing event that results in the skipping of the polyadenylation sites at IPW, leading to 
the neuron-specific expression of UBE3A-ATS and subsequent imprinted expression of 
UBE3A. In this paper, we investigated whether depletion of RBFOX1 and RBFOX2 
altered SNURF/SNRPN lncRNA expression and/or processing during neural 
differentiation. We mutated RBFOX1 and RBFOX2 singly and in combination using 
lentiCRISPRs in AS and normal patient-derived iPSCs and differentiated them into 
neurons. We found that RBFOX1 and RBFOX2 are not required for the neuron-specific 
expression or processing of the SNURF/SNRPN. However, we found a neural 
differentiation defect in RBFOX2-null iPSCs, suggesting that RBFOX2 is involved in 
division versus differentiation decisions in iPSC-derived neural progenitors.   
4.3 Materials and Methods 
iPSC Culture 
iPSCs were maintained as described before (Chamberlain et al., 2010). Briefly, 
iPSCs were grown on irradiated mouse embryonic fibroblasts and fed daily with 
conventional hESC medium consisting of DMEM-F12 supplemented with knock-
out serum replacer, nonessential amino acids, L-glutamine, β-mercaptoethanol, 
and basic FGF. iPSCs were cultured in a humid incubator at 37 °C with 5% CO2 
and passaged approximately once a week manually. 
Neural Differentiation 
iPSC-derived neuronal culture were generated using either embryoid-body based 
(Pankratz et al., 2007) or monolayer (Germain et al., 2013) differentiation 
protocol with some modifications as previously reported (Chamberlain et al., 
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2010; Germain et al., 2014). Briefly, iPSC colonies were manually cut and lifted 
when generating embryoid bodies for the embryoid-body protocol. After three 
weeks of neural differentiation using either protocol, neural progenitors were 
plated on tissue culture plates coated with poly-ornithine/laminin. The neural 
differentiation medium consisted of Neurobasal Medium, B-27 supplement, 
nonessential amino acids, and L-glutamine, and was supplemented with 1 μM 
ascorbic acid, 200 μM cyclic adenosine monophosphate, 10 ng/mL brain-derived 
neurotrophic factor, and 10 ng/mL glial-derived neurotrophic factor. Unless 
otherwise specified, all experiments were conducted on neural cultures that were 
at least 10 weeks old. 
Lentiviral Production, Transduction, and Clone-screening 
sgRNAs were designed using web-based CRISPR design tool 
(http://crispr.mit.edu) and cloned into lentiCRISPR (Addgene Plasmid 49535 and 
52961) and lentiGuidePuro (Addgene Plasmid 52963) as instructed (Sanjana et 
al., 2014; Shalem et al., 2014). lentiviral particles were made by transfecting 
293FT cells with 2nd generation packaging systems using lipofectamine 2000 
(Life Technologies). iPSCs were singlized using Accutase (Millipore) and 
transduced with lentivirus in suspension in the presence of 8μg/mL polybrene for 
two hours. The iPSCs/lentivirus mixture were diluted 1:1 in hESC medium and 
plated on DR4 MEF feeders at a low density, supplemented with 10μM ROCK 
inhibitor, Y-27632, overnight. Attached cells were cultured in hESC medium for 
an additional 72 hours before drug selection using puromycin at 0.5μg/mL during 
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the first week and at 1 μg/mL during the second week. Puromycin-resistant iPSC 
colonies were individually picked into a new feeder well and screened for indels 
by sequencing genomic DNA. 
RNA Isolation and Reverse Transcription 
RNA samples were isolated using RNA-Bee (Tel-Test Inc.), DNase-treated with 
Amplification Grade DNaseI (Invitrogen) at 37°C for 45 minute, and converted 
into cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) according to the manufacturer’s instructions. 
Quantitative Reverse Transcription PCR 
All RT-qPCR assays were performed in biological triplicate from independent 
cultures. Expression levels of target genes were measured using Taqman gene 
expression assays (Applied Biosystems) following the manufacturer’s protocol. In 
the case of sno-lncRNAs, gene expression levels were measured using 
published primers (Yin et al., 2012) in combination with SYBR Green PCR 
master mix (Applied Biosystems). All genes were normalized to GAPDH. Relative 
quantity (RQ) value was calculated as 2^-ΔΔCt using un-manipulated AS or normal 
cell lines as the calibrator sample. 
Western Blotting 
Cells were lysed on ice using RIPA buffer (150mM NaCl; 50mM Tris, pH 8.0; 1% 
TritonX-100; 0.5% Sodium Deoxycholate; 0.1% SDS) supplemented with 
proteinase inhibitor II. Protein concentrations were measured using Peirce BCA 
Protein Assay Kit (Thermo Scientific). Total cell lysates were resolved on 10% 
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handcast SDS-PAGE gels and transferred to nitrocellulose or polyvinylidene 
difluoride membranes using wet/tank blotting system (Bio-Rad). The membranes 
were blocked in 5% nonfat dry milk in TBST (0.5% Tween-20 in TBS containing 
20mM Tris and 500mM NaCl). The following primary antibodies and 
concentrations were used: mouse anti-GAPDH (1:3000, MAB374, Millipore), 
rabbit anti-RBFOX2 (1:2000, A300-864A, Bethyl), rabbit anti-RBFOX1 (1:1000, 
ab83574, Abcam). After washing with TBST three times, membranes were 
blotted with corresponding secondary antibodies conjugated with horseradish 
peroxidase. Membranes were washed and then developed in Immobilon Western 
Chemiluminescent HRP Substrate (Millipore), visualized using ChemiDoc Touch 
(Bio-Rad). 
Cross-linking Immunoprecipitation (CLIP) 
CLIP experiments are carried out according to published protocols (Ule et al., 
2005; Yeo et al., 2009). Briefly, RNA-binding proteins are cross-linked to RNA 
transcripts by UV irradiation at 400mJ/cm2. Irradiated cells are lysed and 
subjected to DNase treatment. RBFOX1 and RBFOX2 bound transcripts are 
magnetically pulled down using Protein A Dynabeads (Dynal), which are pre-
conjugated to rabbit anti-RBFOX1 (Abcam) and rabbit anti-RBFOX2 (Bethyl, 
(Yeo et al., 2009)) respectively. An antibody against rabbit IgG is used to assay 
for non-specific binding. After purification steps, transcripts are released by 
proteinase K and isolated as described before. RNA products are reverse-
transcribed followed by conventional PCR analysis.  
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Immunocytochemistry 
Immunocytochemistry was carried out as previously described (Chamberlain et 
al., 2010). The following antibodies and concentrations were used: rabbit anti-
RBFOX2 (1:250, A300-864A, Bethyl), mouse anti-OCT3/4 (1:100, sc-5279, Santa 
Cruz Biotechnology), rabbit anti-Activated-Caspase3 (1:400, #9661, Cell 
Signaling Technology), mouse anti-Ki67 (1:100, M7240, Dako), rabbit anti-TBR1 
(1:500, ab31940, Abcam). AlexaFluor 488 and 594 fluorochrome conjugated 
secondary antibodies (Life Technologies) were used at 1:500. Nuclei were 
counterstained with DAPI and coverslips were mounted on slides with 
Vectashield (Vector Laboratories). Slides were imaged using a Zeiss Axiovision 
microscope or a Zeiss LSM 780 confocal microscope. Cell counting was carried 
out in a double-blind fashion on independent cultures in triplicates. 
Cell Death and Cell Cycle Flow Cytometry 
Cell death analysis was done using Dead Cell Apoptosis Kit with Annexin V 
Alexa Fluor 488 and propidium iodide (Molecular Probes). Seven days after 
splitting, iPSCs were singlized using Accutase (Millipore). Staining was carried 
out according to the manufacturer’s protocol. All experiments were run in 
triplicates using independent cultures. Negative control with no Annexin V and 
propidium iodide staining, Annixin V only control, and propidium iodide only 
control were included using corresponding cell lines to set up gates. Flow 
cytometry analysis was carried out by UCONN Health Flow Cytometry Core, 
using a MACSQuant Analyzer 10. 
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Cell cycle analysis was done using Click-iT Plus EdU Alexa Fluor 647 Flow 
Cytometry Assay Kit (Molecular Probes). Four days after splitting, iPSCs were 
synchronized using 0.2μM of nocodazole for 18 hours. The cells were then 
released into cell cycle for 3.5 hours in hESC medium, followed by 10μM EdU 
labeling for 30 minutes. Cells were then washed and singlized using TrypLE 
Express (Gibco). Staining was carried out according to the manufacturer’s 
protocol. All experiments were run in duplicates or triplicates using independent 
cultures. In addition to EdU-labeling and propidium iodide, iPSCs were also 
stained with mouse anti-OCT3/4 (1:100, sc-5279, Santa Cruz Biotechnology) in 
combination with goat anti-mouse AlexaFluor 488 fluorochrome conjugated 
secondary antibody (1:200, Life Technologies) for pluripotency. Negative control 
(with no EdU, Oct3/4, or propidium iodide staining), EdU-labeling only control, 
Oct3/4 only control, and propidium iodide only control were included using 
corresponding cell lines to set up gates. AlexaFluor 488 fluorochrome conjugated 
secondary antibody was present in all four controls. Flow cytometry analysis was 
carried out by UCONN Health Flow Cytometry Core, using a Becton-Dickinson 
LSR II Flow Cytometer.  
RNA FISH 
RNA fluorescence in situ hybridization was carried out as previously described 
(Martins-Taylor et al., 2014). SNORD116 probes were made from BAC RP11-
186C7 (BACPAC Resources Center). Slides were imaged using a Zeiss LSM 780 
confocal microscope. 
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4.4 RESULTS 
4.4.1 RBFOX2 is expressed ubiquitously throughout in vitro neural differentiation while 
RBFOX1 is expressed in a neuron-specific manner in human. 
Previous studies indicated that RBFOX2 and its protein product are expressed in 
a broad spectrum of tissues and cell types, including hESCs (Underwood et al., 2005; 
Yeo et al., 2009), while RBFOX1 and its protein product are specifically expressed in 
brain and muscle cells (Underwood et al., 2005). We sought to determine the 
expression patterns of RBFOX2 and RBFOX1 RNA and protein during in vitro 
differentiation of human iPSCs into neurons. Conventional PCR and western blotting in 
iPSCs and their neural-derivatives revealed that RBFOX2 is expressed abundantly in 
iPSCs and at all time points during neural differentiation (Figure 4.1A-B). On the other 
hand, RBFOX1 RNA is first evident in the neural precursor stage, but is markedly 
upregulated in 6-week and 10-week neuronal cultures (Figure 4.1A). RBFOX1 protein 
is detectable only in neural cultures that have been maturing in vitro for over 6 weeks 
(Figure 4.1B). Robust expression of RBFOX1 RNA and detectable expression of 
RBFOX1 protein is coincident with the appearance of UBE3A-ATS (Figure 4.1A) 
(Chamberlain et al., 2010). 
4.4.2 SNURF/SNRPN lncRNA transcripts are bound by RBFOX1 and RBFOX2 in 
iPSCs and neurons. 
Since RBFOX1 and RBFOX2 are both RNA-binding proteins (Kuroyanagi, 2009) 
and RBFOX2 was previously shown to bind the SNURF/SNRPN lncRNA, we carried out 
cross-linking immunoprecipitation (CLIP) to see whether the RBFOX proteins bind 
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SNURF/SNRPN in iPSCs and 10-week-old iPSC-derived neurons (Figure 4.1C). We 
found abundant RBFOX2-binding on the SNURF/SNRPN lncRNA expressed in iPSCs 
(i.e. from SNURF/SNRPN to IPW). This finding agrees with previously published 
RBFOX2 CLIP-seq data in hESCs (Yeo et al., 2009). In neurons, where both RBFOX1 
and RBFOX2 are expressed, we found both factors bound to the entire SNURF/SNRPN 
lncRNA, including neuron-specific SNORD115 and UBE3A-ATS. Since RBFOX1 
expression correlated with the appearance of UBE3A-ATS, and since RBFOX proteins 
bind to SNURF/SNRPN lncRNA transcripts, we hypothesized that RBFOX1, by itself or 
together with RBFOX2, may play a role in regulating the expression of the neuron-
specific portion of SNURF/SNRPN transcripts via alternative splicing. 
4.4.3 Loss of RBFOX2 does not affect expression of the lncRNA in iPSCs and neurons. 
To investigate the role of RBFOX2 in the regulation of SNURF/SNRPN lncRNA, 
we knocked out RBFOX2 in AS iPSCs harboring a large deletion of maternal 15q11-q13 
using CRISPR/Cas9. Specifically, we transduced AS iPSCs with lentiviruses carrying 
both Cas9 and sgRNA components (Shalem et al., 2014) to create non-homologous 
end-joining (NHEJ)-mediated insertions/deletions (indels). To account for potential off-
target effects, we designed two different sgRNAs targeting the two most upstream 
exons of RBFOX2 that are common amongst all RBFOX2 transcripts (Figure 4.2A). As 
a control for lentiviral transduction and CRISPR/Cas9 integration and expression, we 
designed a scrambled sgRNA that has no match in the human genome (Shirk et al., 
2013b). For RBFOX2 knockouts (KOs), we amplified and sequenced the genomic DNA 
near the predicted CRISPR/Cas9 cut site to identify small indels that shifted the reading 
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frame, leading to a premature stop codon. We selected two clonal iPSC lines for further 
study.  
We then quantified RBFOX2 mRNA and protein and found reduced levels of 
RBFOX2 mRNA (Figure 4.2C) and undetectable levels of RBFOX2 protein in RBFOX2 
KO iPSCs (Figure 4.2D, F). We also confirmed the functional loss of RBFOX2 by 
assaying splicing changes in previously reported RBFOX2-splicing targets, PICALM and 
TSC2 (Figure 4.2E) (Yeo et al., 2009). Even though RBFOX2 is the only available 
RBFOX paralog expressed in iPSCs, the absence of RBFOX2 did not affect gene 
expression at any portion of the SNURF/SNRPN lncRNA assayed (Figure 4.2G, H). 
Specifically, we quantified SNORD116 host transcript and sno-lncRNAs, which are most 
enriched for RBFOX2 binding (Yeo et al., 2009; Yin et al., 2012), as well as an individual 
processed snoRNA, SNORD116-29, and found no expression differences between non-
transduced, scrambled and RBFOX2 KO iPSCs.  
 Following 10-week in-vitro neural differentiation, we reassessed RBFOX2 
mRNA and protein levels, and ensured that functional loss of RBFOX2 was still evident 
in RBFOX2 KO neurons (Figure 4.3A-C). Since it is known that RBFOX paralogs affect 
each other’s splicing and expression, we also quantified the RNA levels of RBFOX1 and 
RBFOX3, which are expressed in neurons. We observed a slight downregulation of 
RBFOX1 and upregulation in RBFOX3 in RBFOX2 KO neurons. However, these 
changes were also observed in the scrambled control (Figure 4.3A), and are thus 
unlikely to be related to RBFOX2 depletion. As in iPSCs, the absence of RBFOX2 did 
not overtly affect the expression of the SNURF/SNRPN lncRNA (Figure 4.3D, E).  
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To rule out the possibility that RBFOX2 might play a different role in normal 
iPSCs and neurons, we also mutated RBFOX2 in normal iPSCs and differentiated them 
into neurons (Supplementary figure 1).  Although we found slight increases in the 
levels of RBFOX1 and RBFOX3 mRNAs as well as small, but significant increases in 4 
out of 5 sno-lncRNAs in the RBFOX2 KO neurons, we determined that the RBFOX2 KO 
neurons also had increased MAP2 and VGLUT2 levels, suggesting that there are more 
mature neurons in the RBFOX2 KO cultures.  This variability in the neuronal cultures 
may account for the increases in RBFOX1 and RBFOX3 mRNAs and the sno-lncRNAs 
independent of RBFOX2 depletion (Supplementary figure 1I).    
4.4.4 Loss of RBFOX1 does not affect the expression of the SNURF/SNRPN lncRNA in 
neurons. 
We hypothesized that tissue-specific expression of RBFOX1 might play a critical 
role in processing the SNURF/SNRPN lncRNA, leading to the neuron-specific 
expression of UBE3A-ATS and repression of paternal UBE3A. Therefore, we knocked 
out RBFOX1 in AS iPSCs and in RBFOX2 KO AS iPSCs using the lentiCRISPR/Cas9 
approach. The details of the specific mutations further studied are shown in Figure 4.2B. 
Following differentiation into 10-week neurons, we found that RBFOX1 mRNA was 
significantly reduced in RBFOX1 KO and RBFOX1/2 double knockout (dKO) iPSC-
derived neurons (Figure 4.3A). However, RBFOX1 was reduced in neurons derived 
from iPSCs transduced with the scrambled lentiCRISPR as well. We were not able to 
obtain the same lot of RBFOX1 antibody that had worked for Western blot previously. 
Therefore, to assure the absence of functional RBFOX1 protein, we cloned cDNAs from 
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the RBFOX1 KO and RBFOX1/2 dKO neurons to ensure that the remaining RNA 
transcripts harbored frame-shift mutations and lead to premature stop codons 
(Supplementary figure 2). Unexpectedly, in RBFOX1 KO2, we found a subpopulation 
of neurons expressing RBFOX1 cDNA with a complex 57nt deletion that was not 
identified in the original iPSC gDNA. By designing primers specific to the unique DNA 
sequence created by this deletion, we found a very small population of iPSCs 
presenting the same mutation (Supplementary figure 2F). This indicates that RBFOX1 
KO2 was a mixed clone, with the majority harboring a 4nt frame-shift deletion in 
RBFOX1. The functional loss of RBFOX1 in neurons was confirmed by splicing changes 
in previously reported RBFOX1 targets, KCND3 and ABLIM1 (Supplementary figure 
2G) (Gehman et al., 2011). To our surprise, the expression of the SNURF/SNRPN 
lncRNA and UBE3A was not significantly affected in RBFOX1 KO and RBFOX1/2 dKO 
neurons (Figure 4.3D, E).  
4.4.5 RBFOX2 KO iPSCs are viable with normal cell cycle and have no increase in 
apoptosis 
Contrary to Yeo et al. (Yeo et al., 2009), we found that RBFOX2 KO iPSCs in 
both AS and normal background were viable and did not exhibit increased apoptosis 
(Figure 4.4A, Supplementary figure 3A). To confirm this finding, we performed 
immunocytochemistry using an antibody against activated-caspase3 and found no 
significant differences between the controls and RBFOX2 KO iPSCs (Figure 4.4B, 
Supplementary figure 3B). We also tested whether the absence of RBFOX2 affects 
cell cycle. RBFOX2 KO and control iPSCs were synchronized using a nocodazole block 
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and labeled using EdU. We found no differences between RBFOX2 KO iPSCs and 
controls at any stage of the cell cycle (Figure 4.4C, Supplementary figure 3C). This 
indicated that RBFOX2 KO iPSCs also have a normal cell cycle length. 
4.4.6 RBFOX2 KOs exhibit increased proliferation during in vitro neural differentiation. 
Although the iPSCs appeared to be normal, we consistently saw increased 
proliferation of RBFOX2 KO neurons at approximately 7 weeks of differentiation when 
compared to scrambled controls in both normal and AS background. 
Immunocytochemistry using an antibody against Ki67 confirmed that the proliferating 
population is significantly increased in RBFOX2 KO 7-week neuronal cultures when 
compared to controls (Figure 4.5A-B, Supplementary figure 4A-B). This proliferation 
phenotype in RBFOX2 KO neurons is likely to be caused by splicing changes in exon 12 
of NUMB (Figure 4.3C). Exon 12 alternative splicing in NUMB is mediated by RBFOX2 
(Lu et al., 2015), the inclusion of which is pro-proliferation while the exclusion is pro-
differentiation during neural development (Verdi et al., 1999). 
To determine whether this increase in proliferation affects neural cell-fate and, 
hence, the cell population in the 10-week culture, we quantified mRNA levels of neural 
markers in 10-week-old AS neurons (Supplemental figure 5). Markers representing 
neuronal precursors (SOX2, PAX6, and DCX), neurons (TUBB3 and CTIP2), and 
mature astrocytes (S100B) were largely unchanged in RBFOX2 KO neurons. However, 
significant increases in TBR1 and TBR2 were observed in RBFOX2 KO neurons 
(Figure 4.5C, Supplementary figure 4C). TBR2 is a marker of intermediate progenitor 
cells, while TBR1 is a marker for post-mitotic cortical plate neurons (Englund et al., 
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2005). By counting the number of cells that express TBR1 in Figure 4.5D, we found that 
the percentage of TBR1 positive cells in the neuronal culture was comparable between 
the controls and RBFOX2 KO neurons (Figure 4.5E, Supplementary figure 4D-E), 
suggesting that TBR1 may be upregulated in individual cells and that the proportion of 
post-mitotic cortical plate neurons was not increased. 
4.4.7 FRZB mRNA is upregulated in RBFOX2. 
Gene expression changes were previously seen in RBFOX1 knockdown human 
neural progenitor cells (Fogel et al., 2012). We sought to determine whether these 
changes could also be seen in RBFOX1 and RBFOX2 KO neurons. We observed no 
significant expression changes in SV2B, NRXN1, GABRA3, and FRZB in AS RBFOX1 
KO and RBFOX1/2 dKO neurons compared to the controls (Supplementary figure 6). 
However, we observed an increase in FRZB expression in normal and AS RBFOX2 KO 
neurons (Figure 4.5F, Supplementary figure 4F). FRZB protein competes with 
FRIZZLED receptors for Wnt-binding (Harterink et al., 2011; Leyns et al., 1997). 
Increased FRZB levels suggest that Wnt/β-cat signaling may be attenuated in RBFOX2 
KO neurons. Therefore, we quantified AXIN2 expression, which is transcriptionally 
activated by Wnt/β-cat signaling (Lustig et al., 2002). Unexpectedly, we found a subtle 
increase AXIN2 expression, rather than the expected decrease (Figure 4.5F, 
Supplementary figure 4F). These data suggest that although an increase in FRZB 
mRNA is observed in RBFOX2 KO neurons, there may not be an increase in FRZB 
protein because there is not an attenuation of Wnt/β-cat signaling. 
4.5 DISCUSSION 
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RBFOX2 and its paralog, RBFOX1 are RNA binding proteins known to regulate 
alternative splicing in brain (Gehman et al., 2012; Gehman et al., 2011).   Yeo at al. 
showed abundant RBFOX2-binding on the SNURF/SNRPN lncRNA in hESCs (Yeo et 
al., 2009).  We hypothesized that RBFOX1, the neuron-specific paralog of RBFOX2, 
may regulate alternative splicing of the SNURF/SNRPN lncRNA, leading to the skipping 
of the polyadenylation sites in IPW and neuron-specific expression of the distal portion 
of the lncRNA, also known as UBE3A-ATS.  We first determined that expression of the 
RBFOX1 protein is coincident with the appearance of UBE3A-ATS, while RBFOX2 
protein is more broadly expressed, and a third paralog, RBFOX3, is only expressed in 
10-week neuronal cultures, weeks after the initial detection of UBE3A-ATS 
(Supplementary figure 7). Because RBFOX3 was expressed at a time point later than 
the first appearance of UBE3A-ATS, it is unlikely to play a role in regulating UBE3A-ATS 
expression. Subsequently, we found abundant RBFOX2 and RBFOX1 binding across 
the entire SNURF/SNRPN lncRNA in human iPSC-derived neurons, including IPW and 
UBE3A-ATS. These observations supported our initial hypothesis that RBFOX1, by 
itself or together with RBFOX2, may play a role in regulating the expression of the 
neuron-specific portion of SNURF/SNRPN transcripts via alternative splicing. 
To directly test whether RBFOX1 and/or RBFOX2 played a role in the neuron-
specific processing of the SNURF/SNRPN lncRNA, we knocked out RBFOX2 and 
RBFOX1 alone and in combination in AS iPSCs.  These cells have a deletion of the 
maternal allele of chromosome 15q11-q13, allowing us to focus on the RNA transcripts 
originating from the paternal allele.  We used lentiCRISPR/Cas9 technology to generate 
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indels that would create a frameshift and prematurely stop RBFOX protein translation.  
Although puromycin-resistant clones were carefully screened manually and using online 
TIDE (Tracking of Indels by Decomposition) software (Brinkman et al., 2014) to ensure 
that they were clonal populations with the desired deleterious mutations, we found that 
at least one clone harbored a mutation larger than 50 nucleotides, which was not readily 
detectable by TIDE or manual efforts.  The RBFOX1 KO2 clone carried a small portion 
of cells with a 57 nt in-frame deletion, which likely produces a small amount of 
potentially functional RBFOX1 protein (Supplementary figure 2).   All other clones 
were demonstrated to have either loss of RBFOX protein and/or showed only the 
presence of a mutated cDNA that is predicted to make a prematurely terminated protein 
(Supplementary figure 2). 
Upon knocking out RBFOX2 and RBFOX1, individually and in combination, we 
found that SNURF/SNRPN lncRNA expression levels, including the steady-state levels 
of the SNORD116 host gene, an individual processed SNORD116 snoRNA, the sno-
lncRNAs, and the SNORD115 host gene were not altered in iPSCs and in neurons. This 
indicates that even though RBFOX2 and RBFOX1 bind to SNURF/SNRPN lncRNA, 
they are not essential for its processing and neuron-specific expression as we 
hypothesized.  In addition, we found that the absence of RBFOX2 did not change 
SNORD116 localization in the nucleus (Supplementary figure 8), indicating that 
RBFOX2 does not have an obvious role in in nuclear organization of this locus.  The 
unaltered steady-state levels of SNORD115 RNA in RBFOX1KO and RBFOX1/2 dKO 
neurons suggest that RBFOX1 is not regulating alternative polyadenylation as we had 
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originally hypothesized.   It is possible that alternative polyadenylation is regulated by a 
different RNA binding protein, or alternatively, the SNURF/SNRPN lncRNA is truncated 
in non-neurons by a different mechanism.   
In agreement with our results, Yin et al. reported that RBFOX2 knockdown did 
not affect sno-lncRNA levels in PA1 cells (Yin et al., 2012), and further hypothesized 
that RBFOX proteins may be sequestered by the lncRNA-binding.  Our data did not 
address the latter notion.  Yeo et al. reported a positive correlation between the amount 
of RBFOX2 binding and transcript abundance (Yeo et al., 2009), thus, the enrichment 
for RBFOX binding on SNURF/SNRPN lncRNA and its processed products may reflect 
the abundance of these RNA transcripts. We did not observe increased cell death in 
RBFOX2 knockout iPSCs as previously reported in RBFOX2 knockdown hESCs (Yeo et 
al., 2009). The disparity in viability may be due to differences between RBFOX2 
knockdown versus knockout, but is most likely either caused by differences in the 
culture system (i.e. feeder-free versus MEF feeders) for the pluripotent stem cells or 
shRNA toxicity.  
Despite the fact that many important neuronal genes are targets of RBFOX2 and 
RBFOX1 for alternative splicing, we were able to differentiate all of the RBFOX knockout 
iPSC lines into mature cortical neurons, demonstrating that the proteins are dispensible 
for neuronal differentiation. CNS-specific RBFOX2 and/or RBFOX1 knockout mice were 
viable and had morphologically normal cortical layers, which supports our observation 
(Gehman et al., 2012; Gehman et al., 2011). However, there was a significant increase 
in proliferation at around 7-weeks of neural differentiation in RBFOX2 KO neurons, 
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despite normal cell cycle in iPSCs (Figure 4.4C, Supplementary figure 3C). This 
suggests that RBFOX2 may play an important role in the decision between self-renewal 
and differentiation during neural development. We found increased inclusion of the pro-
proliferative exon 12 of NUMB in RBFOX2 KO neurons, which may provide an 
underlying mechanism for this proliferation phenotype.  We measured mRNA levels of 
neural markers in mature RBFOX2 KO neurons to determine whether this increase in 
proliferation affects neural cell-fate. While most neural markers remained unchanged, 
we found that TBR1 and TBR2 were significantly upregulated in 10-week-old RBFOX2 
knockout neurons. PAX6, TBR2, and TBR1 are expressed sequentially during 
glutamatergic neocortical development (Englund et al., 2005). With no change in PAX6 
level and significant increases in both TBR2 and TBR1 levels in RBFOX2 knockout 
neurons, we hypothesized that there was an over-proliferation in the TBR2+ 
intermediate progenitor population, leading to an increase in the post-mitotic TBR1+ 
neurons. However, the percentage of TBR1+ neurons was not increased in RBFOX2 KO 
neuron cultures, although many TBR1+ neurons reside in multi-layered hubs that are 
hard to image and quantitate using microscopy (Supplementary figure 9). 
We also sought to verify previously reported gene expression changes that were 
observed in RBFOX1 knockdown human neural precursor cells (Fogel et al., 2012).   
One of the genes analyzed, FRZB, was reported to be downregulated in RBFOX1 
knockdown human neural progenitor cells (Fogel et al., 2012). While we did not see a 
change in FRZB in RBFOX1 knockout neurons, we observed a significant increase in 
FRZB in RBFOX2 knockout neurons (Figure 4.5F, Supplementary figure 4F). FRZB 
! 92!
protein is a Wnt signaling antagonist that competes with FRIZZLED receptors for Wnt-
binding (Harterink et al., 2011; Leyns et al., 1997). The canonical Wnt/β-cat pathway 
was not attenuated in RBFOX2 knockout neurons based on the level of AXIN2 (Figure 
4.5F, Supplementary figure 4F). It is possible that despite increased FRZB mRNA, 
FRZB protein was not increased. However, since Wnt-Frizzled signaling can activate 
various non-canonical pathways in addition to the β–catenin pathway (Cadigan and Liu, 
2006; Lu et al., 2004), other aspects of Wnt signaling may be altered in RBFOX2 KO 
neurons. As Wnt-Frizzled signaling regulates many aspects in neurodevelopment, such 
as neuronal migration (Pan et al., 2006), neuronal polarity (Hilliard and Bargmann, 
2006), and axon guidance (Wolf et al., 2008), it will be interesting to determine whether 
other Wnt signaling pathways function normally in RBFOX2 KO neurons. 
Our previously published transcriptome data shows that the FPKM values for 
RBFOX1, RBFOX2, and RBFOX3 are 16.5, 50.2, 5.8, respectively, in AS neurons and 
16.5, 63.9, 6.8, respectively, in normal neurons (Germain et al., 2014). The fact that 
RBFOX2 is much more abundant than RBFOX1 in neurons at the developmental stage 
we assessed may explain why more severe phenotypes were observed in the absence 
of RBFOX2. Because of the highly conserved RNA-binding-motif between RBFOX1 and 
RBFOX2, we expected that they functionally compensate each other to a certain extent. 
However, the RBFOX1/2 dKO neurons presented milder gene expression changes in 
trend with RBFOX2 KO neurons, and showed similar splicing changes to RBFOX2, 
rather than RBFOX1, knockout neurons (Figure 4.3C, Supplementary figure 2G). This 
observation supports our notion that RBFOX2, the most abundant RBFOX paralog, 
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plays a larger role than the other RBFOX proteins in these neurons. It is curious that the 
RBFOX1/2 dKO neurons have a slightly milder phenotype compared to RBFOX2 KO 
neurons.  However, the most apparent phenotype in the RBFOX2 KO neurons is the 
increased proliferation in immature neural cultures.  Perhaps the loss of RBFOX1 
counteracts this increased proliferation.     
In conclusion, RBFOX1 and RBFOX2 are not required for processing of 
SNURF/SNRPN lncRNA, despite the fact that the lncRNA is highly bound by the 
RBFOX proteins. The absence of RBFOX1 did not overtly affect expression or splicing 
for genes assayed here and did not present observable phenotypes in in vitro derived 
human neurons. On the other hand, the absence of RBFOX2 led to a proliferation 
phenotype in immature neural cultures and altered the expression of some genes that 
are important for glutamatergic neocortical development and Wnt-Frizzled signaling. 
These data support the idea that RBFOX1 and RBFOX2 are not completely functionally 
redundant (Gehman et al., 2012). 
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Figure 4.1. RBFOX expression and binding during neural differentiation (iPSC: 
induced pluripotent stem cell; EB: embryoid body; NP: neural precursor; NS: neural 
sphere; Neu: neuron). A) Conventional RT-PCR showing RNA expression of RBFOX2, 
RBFOX1, UBE3A-ATS, and GAPDH over 10 weeks of in vitro neural differentiation. B) 
Western blots showing protein expression of RBFOX2 and RBFOX1. GAPDH was used 
as a loading control. C) RBFOX2 and RBFOX1 bind to SNURF/SNRPN lncRNA in 
iPSCs and 10-week-old neurons. Rabbit IgG served as a negative control for non-
specific binding. 
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Figure 4.2. Lentiviral CRISPR/Cas9-mediated RBFOX KO in AS iPSCs. A and B) 
Schematic of RBFOX2 and RBFOX1 splicing patterns according to the alternative 
splicing graph from Swiss Institute of Bioinformatics on UCSC genome browser. 
Targeted exons are colored in red and the numbers correspond to respective sgRNAs. 
gDNA sequencing shows frameshift indels leading to premature stop codon in two 
RBFOX2 KOs, two RBFOX1 KOs, and one RBFOX1/2 dKO (¶see supplemental figure 
! 96!
2). C) RT-qPCR, D) western blot, and F) immunocytochemistry showing RBFOX2 
mRNA or protein expression in RBFOX2 KO iPSCs. E) Splicing changes in TSC2 and 
PICALM showing functional loss of RBFOX2. G and H) The expression of transcripts 
from SNURF/SNRPN lncRNA, including SNORD116 and sno-lncRNAs, was not altered 
in RBFOX2 KO iPSCs. 
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Figure 4.3. Expression of transcripts from SNURF/SNRPN lncRNA was not altered 
in RBFOX KO AS iPSC-derived neurons. A) RT-qPCR showing RBFOX2 and 
RBFOX1 expression in respective KO neurons. B) Western blot of RBFOX2 protein in 
KO neurons. C) Splicing changes in TSC2 and NUMB in RBFOX2 KO neurons. D and 
E) Expression of transcripts from SNURF/SNRPN lncRNA, including SNORD116 and 
sno-lncRNA, in RBFOX KO neurons. 
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Figure 4.4. Cell death and cell cycle analysis in RBFOX2 KO AS iPSCs. A) Flow 
cytometry analysis using Annexin V and propidium iodide, to identify viable, necrotic, or 
apoptotic cells. B) Apoptotic cells labeled with activated caspase-3 (green). C) Flow 
cytometry was used to analyse cell cycle in synchronized iPSCs.  Cells were labeled 
with EdU during S-phase, and then stained with propidium iodide. 
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Figure 4.5. 7-week-old AS RBFOX2 KO neurons showed increased proliferation 
and 10-week-old AS RBFOX2 KO neurons showed increased TBR1, TBR2, and 
FRZB expression. A) Proliferating cells in 7-week-old neural culture labeled with 
antibody against Ki67 (green). B) Quantification of Ki67+ cells in A. C) RT-qPCR 
showing TBR1 and TBR2 expression in 10-week-old RBFOX2 KO neurons. D) 10-
week-old RBFOX2 KO neurons labeled with antibody against TBR1 (green). E) 
Quantification of TBR1+ cells in D. F) RT-qPCR showing FRZB and AXIN2 expression 
in 10-week-old RBFOX2 KO neurons. 
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Supplementary Figure 1. Lentiviral CRISPR/Cas9-mediated RBFOX2 KO in Normal 
iPSCs. The expression of SNURF/SNRPN lncRNA was not altered in RBFOX KO AS 
iPSCs and iPSC-derived neurons.  A) Schematic of RBFOX2 splicing pattern according 
to alternative splicing graph from Swiss Institute of Bioinformatics on UCSC genome 
browser. Targeted exon is colored in red. gDNA sequencing shows frameshift indels 
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leading to premature stop codon in the RBFOX2 KO. B, C, and E) RT-qPCR, western 
blot, and immunocytochemistry showing RBFOX2/RBFOX2 expression in the RBFOX2 
KO iPSCs. D) Splicing changes in TSC2 and PICALM showing functional loss of 
RBFOX2. F and G) RT-qPCR to quantify transcripts from the SNURF/SNRPN lncRNA, 
including SNORD116 and sno-lncRNAs in RBFOX2 KO iPSCs. H) RT-qPCR showing 
reduced RBFOX2 expression in RBFOX2 KO neurons. I) Increased MAP2 and VGLUT2 
expression corresponded with increased RBFOX1 expression in H.  J) Western blot 
showing loss of RBFOX2 in KO neurons. K) Splicing changes in TSC2 showing 
functional loss of RBFOX2 in KO neurons. L and M) RT-qPCR to quantify transcripts 
from SNURF/SNRPN lncRNA, including SNORD116 and sno-lncRNAs, in RBFOX KO 
neurons. 
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Supplementary Figure 2. Sequencing analysis for RBFOX1 mutations in AS 
RBFOX1 KO iPSCs and neurons. A and B) gDNA sequencing in iPSCs and neurons 
as well as cDNA sequencing by pBluescript cloning of PCR products in AS RBFOX1 
KO1 and KO2. C) Sequencing alignment between representative AS RBFOX1 KO2 
pBluecript cloning product and control wild type sequence, showing a complex 57 
nucleotide deletion. D) The 57 nucleotide deletion in C was not picked up by TIDE in AS 
RBFOX1 KO2 neuronal gDNA due to the software’s size limitation on indels. E) AS 
RBFOX1 KO2 neuronal gDNA trace file showing mutations that can be resolved into the 
57 nucleotide deletion by hand. F) By conventional PCR, 3% agarose gel image showed 
a small population of AS RBFOX1 KO2 iPSCs harbors the 57 nucleotide deletion 
(arrowhead), which was better detected using primers specific to the deletion. G) 
Splicing changes in KCND3 and ABLIM1 showing functional loss of RBFOX1 in AS 
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RBFOX1 KO and RBFOX1/2 dKO neurons. Differences in these spliced isoform ratio 
were observed in the scrambled neurons, which has lower RBFOX1 expression than the 
control neurons (Figure 3A). 
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Supplementary Figure 3. Cell death and cell cycle analysis in RBFOX2 KO normal 
iPSCs. A) Flow cytometry analysis using Annexin V and propidium iodide, to identify 
viable, necrotic, or apoptotic cells. B) Apoptotic cells labeled with activated caspase-3 
(green). C) Flow cytometry was used to measure cell cycle in synchronized iPSCs. Cells 
were labeled with EdU during S-phase, and then stained with propidium iodide.  
! 105!
 
Supplementary Figure 4. 7-week-old normal RBFOX2 KO neurons showed 
increased proliferation and 10-week-old normal RBFOX2 KO neurons showed 
increased TBR1, TBR2, and FRZB expression. A) Proliferating cells in 7-week-old 
neural culture labeled with antibody against Ki67 (green). B) Quantification of Ki67+ 
cells in A. C) RT-qPCR showing TBR1 and TBR2 expression in 10-week-old RBFOX2 
KO neurons. D) 10-week-old RBFOX2 KO neurons labeled with antibody against TBR1 
(red). E) Quantification of TBR1+ cells in D. F) RT-qPCR showing FRZB and AXIN2 
expression in 10-week-old RBFOX2 KO neurons.  
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Supplementary Figure 5. RT-qPCR for neural markers in AS neurons. 
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Supplementary Figure 6. RT-qPCR for genes previously shown to change in 
RBFOX1 knockdown human neural progenitor cells. 
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Supplementary Figure 7. Western blot showing RBFOX3 protein expression is 
only detectable in 10-week-old neuronal culture during neural differentiation. 
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Supplementary Figure 8. RNA fluorescence in situ hybridization showing that 
localization of SNORD116 transcripts (white arrow heads, labeled in green) is not 
altered in the absence of RBFOX2 protein. 
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Supplementary Figure 9. Representative confocal microscopic images of TBR1+ 
cells (green) in multilayered hubs in 10-week-old neuronal culture from three 
independent experiments. 
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Supplementary Table 1. List of primers. 
Primers for conventional PCR 
Gene Forward Primer Reverse Primer Ref. 
RBFOX1 GACACAATGGCTCAGCCTTAC CGGAACCTGAAGGGGATATT  
RBFOX2 GGTGGAAAAGAAAGCTGTGG GTGGTGGAAATGGGATGGTA  
UBE3A-ATS AAGGCCTGGAATCTGATCCT CCTAGATTTTAAATAGACAATCCAAAG (Runte et al., 2001) 
PICALM ATTCCATATCCTATCATGCCTGT AATTGGAGTCAACCAGGTGAA (Yeo et al., 2009) 
TSC2 CGGTCCAATGTCCTCTTGTC TCCAGGTGGAGGTTTTTCAG (Yeo et al., 2009) 
NUMB (exon 12) ATCTGCTCCGATGACCAAAC GAGAGGCAGCACCAGAAGAT  
KCND3 AAGACCACCTCACTCATCG TTCTTGTGGATGGGTAGTTC  
ABLIM1 CTCCATCAACTCCCCTGTGT TAGATGGGTGGCTTTCGGTA  
Taqman RT-qPCR 
Gene Assay ID 
RBFOX1 Hs01125659_m1 
RBFOX2 Hs00204814_m1 
RBFOX3 Hs01370653_m1 
SNRPN Hs00256090_m1 
PAR5 Hs03453940_s1 
SNORD116 Hs03454084_m1 
SNORD116-29 Hs03300097_s1 
IPW Hs03455409_s1 
SNORD115 Hs03454279_m1 
UBE3A Hs00166580_m1 
SOX2 Hs01053049_s1 
PAX6 Hs00240871_m1 
DCX Hs00167057_m1 
TUBB3 Hs00964962_g1 
CTIP2 (BCL11B) Hs01102259_m1 
S100B Hs00902901_m1 
MAP2 Hs00258900_m1 
VGLUT2 (SLC17A6) Hs00220439_m1 
GAD1 Hs01065893_m1 
TBR1 Hs00232429_m1 
TBR2 (EOMES) Hs00172872_m1 
SV2B Hs00208178_m1 
NRXN1 Hs00985123_m1 
GABRA3 Hs00968132_m1 
FRZB Hs00173503_m1 
AXIN2 Hs00610344_m1 
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(Continued from previous page) 
CLIP primers  
Gene Forward Primer Reverse Primer 
SNRPN CCAACCTCTGGCATAAATGG GACCTTCAGCCATCCAAAGA 
PAR5 AGGTGCTTTTGCTTTGCCTA TCTCTGAACCCCAACAGCTT 
SNORD108 TGAGGTCCAGCCTTGCTAAT CCACAATTCAAACCATGCAA 
SNRPN (RBFOX2 cluster) TAATTGGCCTCTTGGGACTG TGACCATTCCCTTCTCCTGT 
SNORD116 TCATAGTGCAGCCAGGACAG TTTTCCTTGCATTGGACACA 
IPW TCTTCTGCCTCCTGTCTCGT TCCCATCACCACAGTGAAAA 
PAR1 AGCTGCCCACACCCATATAC GTGGGGGCTCACACATAACT 
SNORD115 TGGACACATGTCCTCCTCCT TGGGATCTCAGCATCCTCTT 
UBE3A-ATS(9) GCCTTTGGAGACAACTTCCA AGCCCTGAATTCTCACAGAAA 
UBE3A-ATS(3) AGTCTTGGGCTTCCTTTGGT     GAGGAACCATTGCAGCTGAT 
UBE3A-ATS(1) ACTTGGGCTCTACTCGCAAA TGGCAAGTGAGTGTGCCTAA 
SYBR Green RT-qPCR 
Gene Forward Primer Reverse Primer Ref. 
GAPDH TACTAGCGGTTTTACGGGCG TCGAACAGGAGGAGCAGAGAGCGA (Cruvinel et al., 2014) 
sno-lncRNA 1 CTTGGCGTATTCATGGAGGT ACCGGCTAAGTGAGCTGAAA  (Yin et al., 2012) 
sno-lncRNA 2 TGTCCTTGACTCCTGGCTCT  ATGCCAGGTGATTGGAACTC  (Yin et al., 2012) 
sno-lncRNA 3 CGTGCATCCCTATGTACGTG  CAATGCTACCTGGGAGGTGT  (Yin et al., 2012) 
sno-lncRNA 4 GGCCAGAGACAGGCAGATAG  GTATCTCCGCAGCTCACACA  (Yin et al., 2012) 
sno-lncRNA 5 GGAACCAGGGCATAGTGAGA  TTGGATTTGGATGTTGACCA  (Yin et al., 2012) 
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Chapter 5 
General Discussion and Future Direction 
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5.1 General Discussion 
 For rare “orphan” diseases, such as AS, PWS, and Dup 15q syndrome, current 
treatments are often limited to symptom management and behavioral therapies. To 
develop effective disease-specific treatments, it is necessary to understand the genetic 
causes and molecular mechanisms that lead to disease manifestation. With advances in 
sequencing and cytogenetic technologies, scientists have gained significant insights on 
disease genetic causes from patient samples, especially those carrying rare mutations. 
About two decades ago, scientists identified AS as a monogenic disorder caused by 
loss of the maternal UBE3A (Kishino et al., 1997). Recently, using patient samples with 
rare microdeletions, the PWS critical region was narrowed down to a 91 kb stretch of 
DNA that encodes for SNORD116 and IPW (Bieth et al., 2015). Because of 
heterogeneity in Dup 15q disease presentation and difficulties in accurate clinical 
assessment, the genetic cause for Dup 15q syndrome is not as well understood. The 
general consensus is that maternally inherited duplication of chromosome 15q11-q13.1 
leads to Dup 15q syndrome, and that additional genetic or environmental factors may 
contribute to variations in disease phenotype (Battaglia, 2008). Molecular mechanisms 
for disease manifestation can be hard to determine even for diseases with a single or 
few genetic cause(s), such as AS and PWS, respectively. This results from our limited 
knowledge on the function and/or targets of the gene products of UBE3A, SNORD116, 
and IPW. With improved molecular tools and advancement in the biology of protein and 
non-coding RNA, it is hopeful that we will be able to decipher the precise molecular 
pathway for these disorders in the foreseeable future.   
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 AS, PWS, and Dup 15q syndrome iPSCs were useful in understanding gene 
regulation at chromosome 15q11-q13.1, as demonstrated in Chapter 2. Due to the fact 
that chromosome 15q11-q13.1 gene regulation diverges between human and mice, this 
was the first time we were able to study the underlying gene contributions in the most 
relevant tissue—human neurons. This new model system also allowed us to study 
chromosome 15q11-q13.1 gene expression at various developmental time points. We 
found that different parts of SNURF/SNRPN lncRNA exhibit different tissue-specificity—
the more distal, the more neuron-specific (Chamberlain et al., 2010). Our observation in 
PWS SD iPSCs suggests the presence of a boundary element near IPW in non-
neuronal cells that suppresses downstream SNURF/SNRPN lncRNA expression 
(Martins-Taylor et al., 2014). Moreover, chromatin structure and arrangement in neurons 
may play a important role in controlling gene expression at this locus, evidenced by 
gene expression changes in int dup(15) iPSC-derived neurons (Germain et al., 2014). In 
Chapter 4, we disproved our hypothesis and showed that RBFOX1 and RBFOX2 are 
not required for expressing or processing SNURF/SNRPN lncRNA by creating 
knockouts using CRISPR/Cas9. While this result was disappointing, we found other 
changes during neural differentiation in RBFOX2 knockout neurons, indicating that it 
may be involved in division versus proliferation decisions, glutamatergic neocortical 
development, and Wnt-Frizzled signaling. Finally, using gene expression as a readout, 
our iPSC models for AS, PWS and Dup 15q syndrome are useful tools for drug 
development, such as topotecan and mithramycin (Germain et al., 2014; King et al., 
2013; Martins-Taylor et al., 2014).  
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CRISPR/Cas9 technology largely improved the efficiency and ease in human 
genome editing. We demonstrated the versatility of CRISPR/Cas9 as a genome-editing 
tool for human iPSCs. Discovery of iPSC technology to reprogram somatic cells back to 
a pluripotent stage revolutionized the field of disease modelling. Together, our expertise 
in CRISPR/Cas9 genome editing and iPSC technology holds great promise to elucidate 
disease mechanisms and develop therapeutic treatments for AS, PWS, and Dup 15q 
syndrome.  
5.2 Future Direction 
 We would like to identify disease-relevant cellular phenotypes in AS, PWS, and 
Dup 15q iPSC-derived neurons. We will employ techniques like electrophysiology and 
microscopy to find quantifiable phenotypical changes, such as neuron excitability and 
neurite elaboration, respectively. To distinguish disease phenotypes from potential 
contributions from genetic background, it will be ideal to obtain isogenic controls for 
each cell line. The isogenic controls will also be useful for transcriptome analysis to 
identify downstream gene expression changes that may contribute to disease 
manifestation. Quality control for iPSC-derived neurons may be required to minimize 
batch-to-batch differences that cannot be attributed to disease genotype. Our current 
drug screening relies on gene expression changes that cannot be assessed quickly and 
easily and, therefore, is limited in terms of scope. With reliable and quantifiable cellular 
phenotypes, we will be able to adapt our iPSC-derived neurons for high throughput drug 
screening at a much larger scale. 
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 Our current neural differentiation protocols produce cortical neurons. Since 
clinical features in PWS patients suggest a dysfunction in the hypothalamic system 
(Swaab, 1997), it may be important to establish a neural differentiation protocol that 
generates hypothalamic neurons in our lab. Recently, two separate groups published 
hypothalamic neural differentiation protocols (Merkle et al., 2015; Wang et al., 2015), 
which would be helpful in this endeavor. It will be interesting to see if PWS-relevant 
phenotypes, such as perturbation in the oxytocin pathway, can be observed in PWS 
iPSC-derived hypothalamic neurons (Grinevich et al., 2014). 
 As discussed previously in Chapter 3, we would like to re-design the targeting 
construct and sgRNA to generate a new UBE3A-GFP reporter cell line using AS iPSCs. 
Addition to changes proposed previously, we can utilize a split GFP-tagging system to 
improve protein stability by attaching a 15 aa GFP subunit 11 to UBE3A protein and 
expressing subunit 1-10 separately from the AAVS1 safe harbor locus (Cabantous and 
Waldo, 2006). When expressed, GFP subunit 11 and subunit 1-10 associate 
spontaneously to form fluorescent GFP. Moreover, to improve signal detection, 
fluorescence intensity can be amplified by tagging UBE3A protein with up to 7 copies of 
GFP subunit 11. This UBE3A-GFP reporter cell line will be useful for determining the 
developmental time point of paternal UBE3A silencing as well as UBE3A protein 
localization during human neurodevelopment. It can also be used for fluorescence-
based high throughput drug screening to identify chemicals or small molecules that re-
activate paternal UBE3A in mature neurons. Last but not least, a remaining task in the 
AS field is to understand UBE3A protein function. Robust assay development assessing 
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disease-relevant UBE3A targets, such as Ephexin5 and GAT1, could be instrumental for 
drug development.  
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Appendix A. Primers used in Chapter 3 for UBE3A-GFP reporter. Primer sets 
indicate in the brackets correspond to Figure 3.1B. 
 
Screening 
Purpose Forward Primer Reverse Primer 
Product 
Size 
(bp) 
HotSHOT DNA 
GFP+ tSNRP GFP 1F ACGTAAACGGCCACAAGTTC tSNRP GFP 1R GTCCTCCTTGAAGTCGATGC  338 
Neo+ Neo F TGAATGAACTGCAGGACGAG Neo R ATACTTTCTCGGCAGGAGCA 171 
HotSHOT DNA (Cre-Lox Recombination) 
WT 
[A; B] 
Ube3aGFP_Cre_Fa2 
TATGGGGCTCACATTGGTTT 
Ube3aGFP_Cre_Rb2 
GAAACACTGCTGGCAATATGA 194 
Targeted Neo- 
[A; B] 
[A; D] 
Ube3aGFP_Cre_Fa2 
TATGGGGCTCACATTGGTTT 
Ube3aGFP_Cre_Rb2 
GAAACACTGCTGGCAATATGA 
Ube3aGFP_Cre_Rd 
TCGAGGGACCTAATAACTTCG 
285 
198 
Targeted Neo+ 
[A; C] 
Ube3aGFP_Cre_Fa 
CCTTGCATTCCTCGTCACAT 
Ube3aGFP_Cre_Rc 
TAAAGCGCATGCTCCAGACT 472 
gDNA 
5’ Homologous 
Recombination 
[5’ F; 5’ R] 
UBE3A_GFP_5 F2 (1° PCR) 
CTGCCTCTACTTAAACGTACAGAAAA 
UBE3A_GFP_5 F1 (2° PCR) 
AGAACTCAAACTAACATAAGTGTCATTAAAA 
UBE3A_GFP_5 R 
AAGTTATATTAAGGGTTATTGAATATGATCG 
1552 
1266 
3’ Homologous 
Recombination 
[3’ F; 3’ R] 
UBE3A_GFP_3 F 
AACTACAACAGCCACAACGTCTATATC 
UBE3A_GFP_3 R1 (1° PCR) 
GATCTACAGTAATCAGTTAAAACAATCAGTC 
UBE3A_GFP_3 R2 (2° PCR) 
TCTCACCTTAGTTAAAAATACATAATCCTTT 
1785 
1681 
WT UBE3A 
[WT F; WT R] 
UBE3A_intron12_F1 (1° PCR) 
GGCAACTTGGTAGTTACACAACA 
UBE3A_intron12_F2 (2° PCR) 
CCCATGACTTACAGTTTTCCTG 
CRISPR_cut R 
TTTGGCATACGTGATGGCCT 
269 
150 
UBE3A-GFP 
Sequencing 
UBE3A_intron12_F1 (PCR) 
GGCAACTTGGTAGTTACACAACA 
UBE3A_intron12_F2 (Seq 
primer) 
CCCATGACTTACAGTTTTCCTG 
tSNRP GFP 1R 
GTCCTCCTTGAAGTCGATGC 650 
cDNA 
WT UBE3A 
expression 
UBE3A ex12 F 
ACCTGTGGGAGGACTAGGAA 
UBE3A ex13 R 
GGCATACGTGATGGCCTTCA 163 
UBE3A-GFP 
expression 
UBE3A ex12 F 
ACCTGTGGGAGGACTAGGAA 
UBE3A_GFP cDNA R 
CTGAACTTGTGGCCGTTTAC 231 
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